S&W Seed (SANW) 10-K 27 Sep 23 2023 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2023	Sep. 20, 2023	Dec. 31, 2022
Cover [Abstract]
Entity Registrant Name	S&W SEED CO
Entity Central Index Key	0001477246
Document Type	10-K
Document Period End Date	Jun. 30, 2023
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-34719
Entity Tax Identification Number	27-1275784
Entity Address, Address Line One	2101 Ken Pratt Blvd
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Longmont
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80501
City Area Code	720
Local Phone Number	506-9191
Entity Public Float			$ 36,065,100
Entity Common Stock, Shares Outstanding		43,001,172
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Trading Symbol	SANW
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	NV
Document Annual Report	true
Document Transition Report	false
Auditor Firm ID	173
Auditor Name	Crowe LLP
Auditor Location	Denver, Colorado
Documents Incorporated by Reference	Portions of the registrant's Proxy Statement for its next Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement is to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended June 30, 2023.

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Jun. 30, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 3,398,793	$ 2,056,508
Accounts receivable, net	24,622,727	19,051,236
Notes receivable, net	6,846,897	0
Inventories, net	45,098,268	54,515,894
Prepaid expenses and other current assets	4,099,027	1,605,987
TOTAL CURRENT ASSETS	84,065,712	77,229,625
Property, plant and equipment, net	10,082,168	16,871,669
Intellectual property, net	21,650,534	23,035,925
Other intangibles, net	8,082,325	11,059,902
Right of use assets - operating leases	2,983,303	4,094,253
Equity method investments	23,059,705	367,970
Other assets	2,066,081	1,128,507
TOTAL ASSETS	151,989,828	133,787,851
CURRENT LIABILITIES
Accounts payable	13,312,180	15,901,116
Deferred revenue	464,707	605,960
Accrued expenses and other current liabilities	8,804,456	10,788,740
Current portion of working capital lines of credit, net	44,900,779	12,678,897
Current portion of long-term debt, net	3,808,761	8,316,783
TOTAL CURRENT LIABILITIES	71,290,883	48,291,496
Long-term working capital lines of credit, less current portion	0	21,703,286
Long-term debt, net, less current portion	4,499,334	3,992,540
Other non-current liabilities	2,102,030	3,587,041
TOTAL LIABILITIES	77,892,247	77,574,363
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 3,323 shares authorized; 1,695 issued and outstanding at June 30, 2023 and June 30, 2022	5,274,148	4,804,819
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 43,004,011 issued and 42,979,011 outstanding at June 30, 2023; 42,608,758 issued and 42,583,758 outstanding at June 30, 2022	43,004	42,609
Treasury stock, at cost, 25,000 shares	(134,196)	(134,196)
Additional paid-in capital	167,768,104	163,892,575
Accumulated deficit	(91,932,808)	(105,873,557)
Accumulated other comprehensive loss	(6,987,791)	(6,560,600)
Non-controlling interests	67,120	41,838
TOTAL STOCKHOLDERS' EQUITY	68,823,433	51,408,669
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	151,989,828	133,787,851
Series B Convertible Preferred Stock
MEZZANINE EQUITY
Preferred stock, $0.001 par value; 3,323 shares authorized; 1,695 issued and outstanding at June 30, 2023 and June 30, 2022	$ 5,274,148	$ 4,804,819

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Jun. 30, 2022
STOCKHOLDERS' EQUITY
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	43,004,011	42,608,758
Common stock, shares outstanding	42,979,011	42,583,758
Treasury stock, shares	25,000	25,000
Series B Convertible Preferred Stock
MEZZANINE EQUITY
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,323	3,323
Preferred stock, shares issued	1,695	1,695
Preferred stock, shares outstanding	1,695	1,695

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenue	$ 73,521,291	$ 71,354,298
Cost of revenue	58,983,210	64,999,136
Gross profit	14,538,081	6,355,162
Operating expenses
Selling, general and administrative expenses	22,430,687	24,470,730
Research and development expenses	5,237,772	7,710,642
Depreciation and amortization	4,768,809	5,460,321
Loss (gain) on disposal of property, plant and equipment	44,335	(31,088)
Goodwill impairment charges	0	1,548,324
Total operating expenses	32,481,603	39,158,929
Loss from operations	(17,943,522)	(32,803,767)
Other (income) expense
Foreign currency loss	859,696	777,913
Government grant income	(1,444,044)	0
Gain on sale of business interest	(38,167,102)	0
Gain on sale of equity investment	(32,030)	(68,967)
Gain on disposal of intangible assets	(1,796,252)	0
Change in contingent consideration obligation	0	(714,429)
Interest expense - amortization of debt discount	1,975,938	898,497
Interest expense, net	4,184,067	2,333,575
Other expenses (income)	1,552,154	(121,273)
Income (loss) before income taxes	14,924,051	(35,909,083)
(Benefit from) provision for income taxes	(763,639)	413,423
Income (loss) before equity in net earnings of affiliates	15,687,690	(36,322,506)
Equity in loss of equity method investees, net of tax	1,252,330	0
Net income (loss)	14,435,360	(36,322,506)
Income attributable to non-controlling interests	25,282	72,844
Net income (loss) attributable to S&W Seed Company	14,410,078	(36,395,350)
Net income (loss) attributable to S&W Seed Company	14,410,078	(36,395,350)
Dividends accrued for participating securities and accretion	(469,329)	(166,298)
Net income (loss) attributable to common shareholders	$ 13,940,749	$ (36,561,648)
Net income (loss) attributable to S&W Seed Company per common share:
Basic	$ 0.34	$ (0.93)
Diluted	$ 0.34	$ (0.93)
Weighted average number of common shares outstanding:
Basic	42,752,759	39,133,681
Diluted	42,935,551	39,133,681

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 14,435,360	$ (36,322,506)
Foreign currency translation adjustment, net of income taxes	(427,191)	(709,774)
Comprehensive income (loss)	14,008,169	(37,032,280)
Comprehensive income attributable to noncontrolling interests	25,282	72,844
Comprehensive income (loss) attributable to S&W Seed Company	$ 13,982,887	$ (37,105,124)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Preferred Stock	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Noncontrolling Interests	Accumulated Other Comprehensive Loss
Beginning Balance, amount at Jun. 30, 2021	$ 74,393,193		$ 36,773	$ (134,196)	$ 149,684,357	$ (69,311,909)	$ (31,006)	$ (5,850,826)
Beginning Balance, shares at Jun. 30, 2021			36,772,983	(25,000)
Stock-based compensation, amount	$ 2,267,180				2,267,180
Mezzanine equity Issuance of Series B convertible preferred stock, amount		$ 4,638,521
Mezzanine equity Issuance of Series B convertible preferred stock, shares		1,695
Issuance of common stock for cash upon exercise of stock options, shares	38,774
Mezzanine equity series B detachable warrant	$ 38,757	$ 38,757
Series B Detachable Warrant	322,972				361,729	(38,757)
Mezzanine equity accrued dividends on Series B convertible preferred stock	127,541	127,541
Accrued dividends on Series B convertible preferred stock	(127,541)					(127,541)
Net issuance to settle RSUs, amount	(192,545)		$ 333		(192,878)
Net issuance to settle RSUs, shares			333,296
Proceeds from sale of common stock, net of fees and expenses, amount	11,777,690		$ 5,503		11,772,187
Proceeds from sale of common stock, net of fees and expenses, shares			5,502,479
Other comprehensive income (loss)	(709,774)							(709,774)
Net income (loss)	(36,322,506)					(36,395,350)	72,844
Mezzanine Equity Ending Balance, amount at Jun. 30, 2022	4,804,819	$ 4,804,819
Mezzanine Equity Beginning Balance, shares at Jun. 30, 2022		1,695
Ending Balance, amount at Jun. 30, 2022	51,408,669		$ 42,609	$ (134,196)	163,892,575	(105,873,557)	41,838	(6,560,600)
Ending Balance, shares at Jun. 30, 2022			42,608,758	(25,000)
Stock-based compensation, amount	$ 1,932,416				1,932,416
Issuance of common stock for cash upon exercise of stock options, shares	2,100		2,100
Issuance of common stock for cash upon exercise of stock options	$ 1,994		$ 2		1,992
Mezzanine equity series B detachable warrant	103,350	$ 103,350
Series B Detachable Warrant	(103,350)					(103,350)
Mezzanine equity accrued dividends on Series B convertible preferred stock	365,979	365,979
Accrued dividends on Series B convertible preferred stock	(365,979)					(365,979)
Subordinated loan & security agreement warrants	1,894,901				1,894,901
Net issuance to settle RSUs, amount	(82,165)		$ 291		(82,456)
Net issuance to settle RSUs, shares			290,698
Proceeds from sale of common stock, net of fees and expenses, amount	128,778		$ 102		128,676
Proceeds from sale of common stock, net of fees and expenses, shares			102,455
Other comprehensive income (loss)	(427,191)							(427,191)
Net income (loss)	14,435,360					14,410,078	25,282
Mezzanine Equity Ending Balance, amount at Jun. 30, 2023	5,274,148	$ 5,274,148
Mezzanine Equity Beginning Balance, shares at Jun. 30, 2023		1,695
Ending Balance, amount at Jun. 30, 2023	$ 68,823,433		$ 43,004	$ (134,196)	$ 167,768,104	$ (91,932,808)	$ 67,120	$ (6,987,791)
Ending Balance, shares at Jun. 30, 2023			43,004,011	(25,000)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ 14,435,360	$ (36,322,506)
Adjustments to reconcile net income (loss) from operating activities to net cash used in operating activities
Stock-based compensation	1,932,416	2,267,180
Allowance for doubtful accounts	11,659	216,466
Inventory write-down	2,778,414	6,365,542
Depreciation and amortization	4,768,809	5,460,321
Gain on disposal of property, plant and equipment	44,335	(31,088)
Gain on disposal of intangible assets	(1,796,252)	0
Gain on sale of business interest	(38,167,102)	0
Gain on sale of equity investment	(32,030)	0
Equity in loss of equity method investees, net of tax	1,252,330	0
Government grant income	(1,444,044)	0
Change in deferred tax provision	(806,479)	78,954
Change in foreign exchange contracts	(63,889)	971,386
Foreign currency transactions	46,283	0
Change in contingent consideration obligation	0	(714,429)
Amortization of debt discount	1,975,938	898,497
Accretion of note receivable	(99,763)
Changes in:
Accounts receivable	(5,840,310)	(422,335)
Inventories	5,755,856	688,903
Prepaid expenses and other current assets	84,605	(104,442)
Other non-current assets	(27,950)	(137,320)
Accounts payable	(2,151,619)	977,036
Deferred revenue	(139,826)	223,586
Accrued expenses and other current liabilities	(1,344,945)	1,226,353
Other non-current liabilities	(149,946)	(15,243)
Net cash used in operating activities	(18,978,150)	(18,373,139)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of business interest	7,000,000	0
Proceeds from partnership transaction	2,000,000	0
Proceeds from disposal of property, plant and equipment	1,417	200,605
Net proceeds from sale of equity investment	400,000	988,504
Additions to property, plant and equipment	(856,716)	(2,098,535)
Capital contributions to partnerships	(172,917)	0
Net cash provided by (used in) investing activities	8,371,784	(909,426)
CASH FLOWS FROM FINANCING ACTIVITIES
Net proceeds from sale of common stock	128,778	11,777,690
Issuance of common stock for cash upon exercise of stock options	1,994	0
Net proceeds from sale of Series B convertible preferred stock	0	5,000,250
Taxes paid related to net share settlements of stock-based compensation awards	(82,165)	(192,545)
Borrowings and repayments on lines of credit, net	9,857,653	1,770,219
Borrowings of long-term debt	4,208,460	868,372
Repayments of long-term debt	(1,743,514)	(1,392,533)
Debt issuance costs	(421,538)	(692,779)
Net cash provided by financing activities	11,949,668	17,138,674
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(1,017)	672,462
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS	1,342,285	(1,471,429)
CASH AND CASH EQUIVALENTS, beginning of the period	2,056,508	3,527,937
CASH AND CASH EQUIVALENTS, end of period	3,398,793	2,056,508
Cash paid during the period for:
Interest	4,380,703	2,357,445
Income taxes	$ 130	$ 276,503

Background and Organization

Background and Organization	12 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 - BACKGROUND AND ORGANIZATION Organization The Company began as S&W Seed Company, a general partnership, in 1980 and was originally in the business of breeding, growing, processing and selling alfalfa seed. The Company incorporated a corporation with the same name in Delaware in October 2009, which is the successor entity to Seed Holding, LLC, having purchased a majority interest in the general partnership between June 2008 and December 2009. Following the Company’s initial public offering in May 2010, the Company purchased the remaining general partnership interests and became the sole owner of the general partnership’s original business. In December 2011, the Company reincorporated in Nevada as a result of a statutory short-form merger of the Delaware corporation into its wholly-owned subsidiary, S&W Seed Company, a Nevada corporation. The Company primarily operates in the United States and Australia. Business Overview Since its establishment, S&W Seed Company, including its predecessor entities, or the Company, has been principally engaged in breeding, growing, processing and selling agricultural seeds. The Company operates seed cleaning and processing facilities in Texas, New South Wales, and South Australia. The Company’s seed products are primarily grown under contract by farmers. Since the Company's initial public offering in May 2010, the Company has actively engaged in expansion initiatives through a combination of organic growth, business acquisitions, strategic partnerships, and development of improved varieties of seeds. Recent initiatives include the following: Shell Partnership On February 6, 2023, S&W and Equilon Enterprises LLC (dba Shell Oil Products US, or Shell), entered into a partnership for the development and production of sustainable biofuel feedstocks through Vision Bioenergy Oilseeds LLC, or Vision Bioenergy. Under the terms of the partnership agreement, S&W contributed production and research facilities, along with certain personal property, including vehicles and other similar equipment, into its Vision Bioenergy subsidiary and subsequently sold a 66 % interest in the subsidiary to Shell. Refer to Note 7 for further information. Trigall Australia Partnership Effective December 23, 2022, the Company’s wholly owned subsidiary, S&W Seed Company Australia Pty Ltd, or S&W Australia, entered into a partnership with Trigall Genetics S.A., or Trigall, for the development and marketing of wheat varieties in Australia. Under the terms of the partnership agreement, S&W Australia transferred certain intellectual property license rights and equipment into a wholly owned subsidiary and subsequently sold an 80 % interes t in the subsidiary to Trigall. The subsidiary was renamed Trigall Australia Pty Ltd, or Trigall Australia. See Refer to Note 7 fo r further information.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation a nd Principles of Consolidation The consolidated financial statements include the accounts of S&W Seed Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and include the assets, liabilities, revenue and expenses of all wholly-owned subsidiaries and majority-owned subsidiaries over which the Company's exercises control. Outside stockholders' interests in subsidiaries are shown in the consolidated financial statements as Noncontrolling interests. The Company own s 50.1 % of a venture based in South Africa named SeedVision Proprietary Limited, or SeedVision. SeedVision is a variable interest entity as defined in ASC 810-10, Consolidation, because no substantive equity contributions have been made to it, and SeedVision is being funded through advances, as needed, from its investors . The Company has concluded that it is the primary beneficiary of SeedVision because it has the power, through a tie-breaking vote on the board of directors, to direct the sales and marketing activities of SeedVision, which are considered to be the activities that have the greatest impact on the future economic performance of SeedVision. The Company owns 51.0 % of Sorghum Solutions South Africa, which is a variable interest entity as defined in ASC 810-10, Consolidation, because no substantive equity contributions have been made to it, and Sorghum Solutions South Africa is being funded through advances, as needed, from its investors . The Company has concluded that it is the primary beneficiary of Sorghum Solutions South Africa because it has the power, through a tie-breaking vote on the board of directors, to direct the sales and marketing activities of Sorghum Solutions South Africa, which are considered to be the activities that have the greatest impact on the future economic performance of Sorghum Solutions South Africa. Because the Company is their primary beneficiary, the financial results of SeedVision and Sorghum Solutions South Africa are included in these financial statements. The Company recorded a combined $ 289,517 of current assets (restricted) and $ 22,082 of current liabilities (nonrecourse) for these entities in our consolidated balance sheets as of June 30, 2023. The Company recorded a combined $ 459,909 of current assets (restricted) and $ 31,307 of current liabilities (nonrecourse) for these entities in our consolidated balance sheets as of June 30, 2022. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions affect many items in the financial statements. These include allowance for doubtful trade receivables, inventory valuation, the carrying value of the Company's equity investments, asset impairments, provisions for income taxes, grower accruals (an estimate of amounts payable to farmers who grow seed for the Company), contingencies and litigation. Significant estimates and assumptions are also used to establish the fair value and useful lives of depreciable tangible and certain intangible assets as well as valuing stock-based compensation. Actual results may differ from those estimates and assumptions, and such results may affect income, financial position or cash flows. The Company believes the estimates and assumptions underlying the accompanying consolidated financial statements are reasonable and supportable based on the information available at the time the financial statements were prepared. However, certain adverse geopolitical and macroeconomic events, such as the ongoing conflict between Ukraine and Russia and related sanctions, the armed conflict in Sudan, and uncertain market conditions, including higher inflation and supply chain disruptions, have, among other things, negatively impacted the global economy, created significant volatility and disruption of financial markets, and significantly increased economic and demand uncertainty. These factors make many of the estimates and assumptions reflected in these consolidated financial statements inherently less certain. Therefore, actual results may ultimately differ from those estimates to a greater degree than historically. Certain Risks and Concentrations The Company’s revenue is principally derived from the sale of seed, the market for which is highly competitive. The Company depends on a core group of signific ant customers. No single customer acco unted for more than 10 % of revenue for the years ended June 30, 2023 and 2022. No customer accou nted for more than 10 % of the Company’s accounts receivable at June 30, 2023 and June 30, 2022. The Company sells a substantial portion of its products to international customers. Sales to international markets represented 70 % a nd 73 % of revenue during the years ende d June 30, 2023 and 2022, respectively. The net book value of fixed assets located outside the United States was 31 % a nd 22 % of total fixed assets at June 30, 2023 and 2022, respectively. The following table shows revenue from external sources by destination country: Years Ended June 30, 2023 2022 United States $ 22,060,338 30 % $ 19,534,824 27 % Australia 17,414,681 24 % 21,673,461 30 % Saudi Arabia 9,781,138 13 % 9,528,777 13 % Mexico 5,502,421 8 % 1,915,370 3 % Libya 4,678,973 6 % 1,739,105 2 % Sudan 2,612,603 4 % 1,443,748 2 % Pakistan 2,494,981 3 % 3,309,800 5 % South Africa 1,620,601 2 % 1,898,467 3 % Argentina 1,162,369 2 % 1,541,402 2 % Algeria 912,040 1 % 430,000 1 % Other 5,281,146 7 % 8,339,344 12 % Total revenue $ 73,521,291 100 % $ 71,354,298 100 % Liquidity and Going Concern The Company continues to monitor the ongoing military conflict between Russia and Ukraine and the armed conflict in Sudan on its business, including its results of operations and financial condition. The Company’s product revenue is predicated on its ability to timely fulfill customer orders, which depends in large part upon the consistent availability and operation of shipping and distribution networks operated by third parties. Farmers typically have a limited window during which they can plant seed and their buying decisions can be shaped by actual or perceived disruptions in the Company’s distribution and supply channels. If the Company’s customers delay or decrease their orders due to potential disruptions in its distribution and supply channels, or if the Company is unable to timely fulfill their orders, this would adversely affect the Company’s product revenue. During the year ended June 30, 2023, the Company experienced numerous logistical challenges due to limited availability of trucks for product deliveries, congestion at the ports, and overall increases in shipping and transportation costs. The Company expects these logistical challenges to persist well into fiscal 2024, which may, among other things, delay or reduce its ability to recognize revenue within a particular fiscal period and harm its results of operations. Excluding the gain recognized in relation to the Vision Bioenergy partnership, the Company is not profitable and has recorded negative op erating cash flows for the last several years. For the year ended June 30, 2023, the Company reported net loss, excluding the gain recognized from the Vision Bioenergy partnership, of $ 23.8 million and net cash used in operations of $ 19.0 million. As of June 30, 2023, the Company had cash on hand of $ 3.4 million. The Compa ny had $ 1.0 million of unused availability from its working capital facilities as of June 30, 2023 (refer to Note 8 for further discussion). In fiscal 2024, the Company is entitled to receive $ 6.0 million from Shell, subject to adjustment in certain circumstances detailed further in Note 7, and $ 1.0 million from Trigall in relation to the partnerships formed in fiscal 2023. The Company is obligated to make an additional $ 0.4 million in capital contributions to Trigall Australia through June 2025. The Company’s Amended and Restated Loan and Security Agreement, or the Amended CIBC Loan Agreement, with CIBC Bank USA, or CIBC, and its debt facilities with National Australia Bank, or NAB, listed under the NAB Finance Agreement, contain various operating and financial covenants (refer to Note 8). Adverse geopolitical and macroeconomic events and other factors affecting the Company’s results of operations have increased the risk of the Company’s inability to comply with these covenants, which could result in acceleration of its repayment obligations and foreclosure on its pledged assets. The Amended CIBC Loan Agreement as presently in effect requires the Company to meet minimum adjusted EBITDA levels on a quarterly basis, and the NAB Finance Agreement includes an undertaking that requires the Company to maintain a net related entity position of not more than USD $ 18.5 million and a minimum interest cover ratio at fiscal year-ends. As of June 30, 2023, the Company failed to meet the CIBC minimum adjusted EBITDA covenant as well as the NAB interest cover ratio covenant, but obtained waivers from both lenders with respect to such non-compliance. While the Company obtained waivers from CIBC and NAB for these failed covenants, there can be no assurance the Company will be successful in meeting its covenants or securing future waivers and/or amendments from its le nders. Currently, the Company does not expect to meet certain of these covenants in fiscal 2024. If the Company is unsuccessful in meeting its covenants or securing future waivers and/or amendments from its lenders and cannot obtain other financing options, it may need to reduce the scope of its operations, repay amounts owed t o its lenders and/or sell certain assets. Further, if the Company cannot renew or find other financing options when its two major debt facilities with CIBC and NAB expire on August 31, 2024 and September 30, 2024 , respectively, it m ay need to reduce the scope of its operations, repay amounts owed to its lenders and/or sell certain assets. These operating and liquidity factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Reclassifications Certain prior year amounts have been reclassified in order to conform to the current year presentation. International Operations The Company translates its foreign operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at the current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of accumulated other comprehensive income (loss). Gains or losses from foreign currency transactions are included in the consolidated statements of operations. For the year ended June 30, 2023, a $ 0.9 million foreign currency transaction gain was recognized within Cost of revenue and a $ 0.9 million foreign currency loss was recorded in Other expenses (income). For the year ended June 30, 2022, a $ 0.5 million foreign currency gain was recognized within Cost of revenue and a $ 0.8 million foreign currency loss was recorded to Other expenses (income). Cost of Revenue The Company records purchasing and receiving costs, inspection costs and warehousing costs in cost of revenue. When the Company is required to pay for outward freight and/or the costs incurred to deliver products to its customers, the costs are included in Cost of revenue. Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation. Cash balances located outside of the United States may not be insured and totaled $ 191,766 and $ 811,551 on June 30, 2023 and 2022, respectively. Cash balances residing in the United States exceeding the Federal Deposit Insurance Corporation limit of $ 250,000 totaled $ 2,957,028 and $ 994,957 on June 30, 2023 and 2022, respectively. Accounts Receivable The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $ 209,757 and $ 233,927 at June 30, 2023 and June 30, 2022, respectively. Inventories Inventories consist of seed and packaging materials. Inventories are stated at the lower of cost or net realizable value, and an inventory reserve permanently reduces the cost basis of inventory. Inventories are valued as follows: Actual cost is used to value raw materials such as packaging materials, as well as goods in process. Costs for substantially all finished goods, which include the cost of carryover crops from the previous year, are valued at actual cost. Actual cost for finished goods includes plant conditioning and packaging costs, direct labor and raw materials and manufacturing overhead costs based on normal capacity. The Company records abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage) as current period charges and allocates fixed production overhead to the costs of finished goods based on the normal capacity of the production facilities. Inventory is periodically reviewed to determine if it is marketable, obsolete or impaired. Inventory that is determined to be obsolete or impaired is written off to expense at the time the impairment is identified. Inventory quality is a function of germination percentage. Our experience has shown that our alfalfa seed quality tends to be stable under proper storage conditions; therefore, we do not view inventory obsolescence for alfalfa seed as a material concern. Hybrid crops (sorghum and sunflower) seed quality may be affected by warehouse storage pests such as insects and rodents. The Company maintains a strict pest control program to mitigate risk and maximize hybrid seed quality. Components of inventory are: As of As of June 30, 2023 June 30, 2022 Raw materials and supplies $ 3,309,211 $ 2,645,764 Work in progress 6,409,554 6,677,980 Finished goods 35,379,503 45,192,150 Inventories, net $ 45,098,268 $ 54,515,894 Property, Plant and Equipment Property, plant and equipment is depreciated using the straight-line method over the estimated useful life of the asset - periods of 5 to 35 years for buildings, 2 to 20 years for machinery and equipment, and 2 to 5 years for vehicles. Intangible Assets Intangible assets acquired in business acquisitions are reported at their initial fair value less accumulated amortization. Intangible assets are amortized using the straight-line method over the estimated useful life of the asset. Periods of 10 to 30 years for technology/IP/germplasm, 5 to 20 years for customer relationships and trade names and 10 to 20 for other intangible assets. The weighted average estimated useful lives are 25 years for technology/IP/germplasm, 19 years for customer relationships, 16 years for trade names, and 18 years for other intangible assets. Investments In fiscal 2023, the Company entered into two partnerships resulting in a 34 % ownership interest in Vision Bioenergy and a 20 % ownership interest in Trigall Australia. Following the initial recording of each investment, the Company assesses and records its share of equity earnings from each investment on a quarterly basis, resulting in the investment carrying value increasing or decreasing depending on whether a gain or loss is recorded. For Trigall Australia, the Company is also required to make capital contributions, which increases the carrying value of the investment. Research and Development Costs The Company is engaged in ongoing research and development, or R&D, of proprietary seed varieties. All R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results have been achieved. The costs associated with equipment or facilities acquired or constructed for R&D activities that have alternative future uses are capitalized and depreciated on a straight-line basis over the estimated useful life of the asset. Employee Retention Credit In response to the COVID-19 pandemic, the Employee Retention Credit, or ERC, was established under the Coronavirus Aid, Relief, and Economic Security Act. The ERC is a refundable tax credit meant for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. Companies who meet the eligibility requirements can claim the ERC on an original or adjusted employment tax return for a period within those dates. In March 2023, the Company determined that it qualifies for $ 1.4 million in relief for the period from April 1, 2021 to September 30, 2021. Upon receipt of the relief, the Company will owe $ 0.2 million in tax advisory costs associated with the assessment of the tax credit. Further research is ongoing to determine if the Company qualifies for any other reporting periods. As there is no authoritative guidance under US GAAP for government assistance to for-profit business entities, the Company accounts for the ERC by analogy to International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance . In accordance with IAS 20, management determined it has reasonable assurance of receipt of the identified ERC amount and recorded the $ 1.4 million benefit under Government grant income in the consolidated statements of operations during the year ended June 30, 2023. A corresponding accrual of the tax credit receivable was recorded under Prepaid expenses and other current assets on the consolidated balance sheets as of June 30, 2023. Income Taxes The Company accounts for income taxes in accordance with the applicable accounting standards. These standards prescribe a minimum threshold a tax position is required to meet before being recognized in the consolidated financial statements. Deferred taxes are recognized for the estimated taxes ultimately payable or recoverable based on the enacted tax law. Changes in enacted tax rates are reflected in the tax provision as they occur. Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate for the years ended June 30, 2023 and 2022 has been affected by the valuation allowance on the Company’s deferred tax assets. Net Income (Loss) Per Common Share Data Basic net income (loss) per common share, or EPS, is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is calculated by adjusting both the numerator (net income (loss)) and the denominator (weighted-average number of shares outstanding) for the dilutive effects of potentially dilutive securities, including options and restricted stock awards. The treasury stock method is used for stock options and restricted stock awards. Under this method, consideration that would be received upon exercise (as well as remaining compensation cost to be recognized for awards not yet vested) is assumed to be used to repurchase shares of stock in the market, with net number of shares assumed to be issued added to the denominator. The Company computes earnings per share using the two-class method. The two-class method requires an earnings allocation formula that determines earnings per share for common shareholders and participating security holders according to dividends declared and participating rights in undistributed earnings. The Series B Redeemable Convertible Non-Voting Preferred Stock, par value $ 0.001 per share, or the Series B Preferred Stock, and warrant are participating securities because holders of such shares have non-forfeitable dividend rights and participate in any undistributed earnings with common stock. Under the two-class method, total dividends provided to the holders of participating securities and undistributed earnings allocated to participating securities are subtracted from net income attributable to the Co mpany in determining net loss attributable to common shareholders. Additionally, any accretion to the redemption value for the Series B Preferred Stock is treated as a deemed dividend in the two-class EPS calculation. The calculation of basic and diluted EPS is shown in the table below: Years Ended June 30, 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 14,410,078 $ ( 36,395,350 ) Dividends accrued for participating securities ( 365,979 ) ( 127,541 ) Accretion of Series B Preferred Stock redemption value ( 103,350 ) ( 38,757 ) Numerator for net income (loss) per common share - basic and diluted $ 13,940,749 $ ( 36,561,648 ) Denominator: Denominator for basic EPS - weighted average shares 42,752,759 39,133,681 Less: weighted average shares - dilutive securities: Employee stock options 50,023 — Employee restricted stock options 132,769 — Denominator for diluted EPS - weighted average shares 42,935,551 39,133,681 Net income (loss) per common share - basic $ 0.33 $ ( 0.93 ) Net income (loss) per common share - diluted $ 0.32 $ ( 0.93 ) Anti-dilutive shares, which have been excluded from the computation of diluted income (loss) per share, included 4,851,886 employee stock options, 1,695,000 shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to purchase 2,633,400 shares of common stock related to the MFP Loan Agreement (as defined below), 559,350 warrants issued with the Company's Series B Convertible Preferred Stock, and 46,770 restricted stock units. The terms and conditions of these securities are more fully described in Note 12, Note 13, and Note 14 in these consolidated financial statements . For the period ended June 30, 2022, all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because net losses were recognized. Impairment of Long-Lived Assets The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted future cash flows. Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. Refer to Note 5 for further impairment discussion. Derivative Financial Instruments The Company’s subsidiary, S&W Australia, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company at times manages through the use of foreign currency derivative financial instruments. The Company has entered into foreign currency forward contracts and foreign currency call options (refer to Note 10) and accounts for these instruments in accordance with ASC Topic 815, “Derivatives and Hedging,” which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. The Company’s foreign currency contracts and options are not designated as hedging instruments under ASC 815; accordingly, changes in the fair value are recorded in current period earnings. Premiums paid for foreign currency options with strike prices below the spot market price when acquired represent the time value of the option, as there is no intrinsic value. Such premiums are recorded as a current asset and amortized over the option term if deemed material. Currency options are measured at fair value if the market price at the reporting date exceeds the strike price. When the strike price exceeds the market price, no liability is recorded as the Company has no obligation to exercise the options. Fair Value of Financial Instruments The Company discloses assets and liabilities that are recognized and measured at fair value, presented in a three-tier fair value hierarchy, as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying value of cash and cash equivalents, accounts payable, short-term and all long-term borrowings, as reflected in the consolidated balance sheets, approximate fair value because of the short-term maturity of these instruments or interest rates commensurate with market rates. There have been no changes in operations and/or credit characteristics since the date of issuance that could impact the relationship between interest rate and market rates. S&W received a $ 6.0 million note receivable due from Shell in connection with the Vision Bioenergy partnership transaction (see Note 7). The note, which is due in February 2024, was initially recorded at its $ 5.7 million present value discounted at a rate of 4.4 %, which is ou r estimated discount rate for similar instruments. The receivable balance is being accreted to the full receivable amount on a straight-line basis over the remaining receivable term due to its short-term maturity. The receivable balance was $ 5.8 million at J une 30, 2023. Also in conjunction with the Vision Bioenergy partnership transaction, S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership transaction, to repurchase a 6 % membership interest from Shell. The option repurchase prices range between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The Purchase Option was valued at $ 0.7 million using a lattice option valuation model. The valuation model incorporated significant, unobservable inputs including a discounted cash flow model based on management projections of future Vision Bioenergy results and an estimate of the current per share value of Vision Bioenergy shares. In the model, the estimate of the current per share value was discounted to account for lack of control and marketability, which were considered to be part of the unit of account given the restrictions of the limited liability company agreement that governs the ownership rights of the members. Other unobservable inputs included the risk-free rates and the estimated future stock volatility based on the historical stock price volatilities of other market participants. A full fair value analysis will be performed at each fiscal year-end or when there is an indication that there may be an impairment to the valuation. Management will estimate and adjust the balance for interim periods. A fair value analysis was performed as of June 30, 2023, which resulted in no material adjustment to the fair value. Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 6/30/23 Valuation Technique Unobservable Input Range Purchase Option $ 695,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 % Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of June 30, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 849,033 $ — Note receivable due from Shell — 5,846,890 — Vision Bioenergy interest purchase option — — 695,000 Total $ — $ 6,695,923 $ 695,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ — Recently Adopted Accounting Pronouncements We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

Leases

Leases	12 Months Ended
	Jun. 30, 2023
Lessee Disclosure [Abstract]
LEASES	NOTE 3 - LEASES S&W leases office and laboratory space, field research plots and equipment used in connection with its operations under various operating and finance leases. Right-of-use, or ROU, assets represent the Company’s right to use the underlying assets for the lease term and lease liabilities represent the net present value of the Company’s obligation to make payments arising from these leases. The lease liabilities are based on the present value of fixed lease payments over the lease term using the implicit lease interest rate or, when unknown, the Company's incremental borrowing rate on the lease commencement date or July 1, 2019 for leases that commenced prior to that date. If the lease includes one or more options to extend the term of the lease, the renewal option is considered in the lease term if it is reasonably certain the Company will exercise the option(s). Operating lease expense is recognized on a straight-line basis over the term of the lease. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component under the practical expedient provisions of the standard. The Company has lease agreements with terms less than one year . For the qualifying short-term leases, the Company elected the short-term lease recognition exemption in which the Company will not recognize ROU assets or lease liabilities, including the ROU assets or lease liabilities for existing short-term leases of those assets upon adoption. Variable lease payments consist primarily of common area maintenance, utilities and taxes, which are not included in the recognition of ROU assets and related lease liabilities. Variable lease payments and short-term lease expenses were immaterial to the Company’s financial statements for the year ended June 30, 2023. The Company’s lease agreements do not contain material restrictive covenants. The components of lease assets and liabilities are as follows: As of June 30, Leases Balance Sheet Classification: 2023 2022 Assets: Right of use assets - finance leases $ 1,759,094 $ 2,071,609 Accumulated amortization - finance leases ( 1,088,294 ) ( 1,131,842 ) Right of use assets - finance leases, net Other assets 670,800 939,767 Right of use assets - operating leases Right of use assets - operating leases 2,983,303 4,094,253 Total lease assets $ 3,654,103 $ 5,034,020 Liabilities: Current lease liabilities - finance leases Current portion of long-term debt, net $ 383,403 $ 804,309 Current lease liabilities - operating leases Accrued expenses and other current liabilities 1,335,568 1,341,198 Long-term portion of lease liabilities - Long-term debt, net, less current portion 304,761 500,723 Long-term portion of lease liabilities - Other non-current liabilities 1,949,604 3,042,311 Total lease liabilities $ 3,973,336 $ 5,688,541 The components of lease cost are as follows: Years Ended June 30, Lease cost: Income Statement Classification: 2023 2022 Operating lease cost Cost of revenue $ 708,802 $ 692,210 Operating lease cost Selling, general and administrative expenses 195,842 307,368 Operating lease cost Research and development expenses 437,282 375,905 Finance lease cost Depreciation and amortization 505,082 625,625 Finance lease cost Interest expense, net 40,817 89,577 Total lease costs $ 1,887,825 $ 2,090,685 Maturities of lease liabilities as of June 30, 2023 are as follows: Fiscal Year Operating Leases Finance Leases 2024 $ 1,454,919 $ 420,368 2025 953,677 212,098 2026 621,696 114,141 2027 397,469 — 2028 99,432 — Total lease payments 3,527,193 746,607 Less: Interest ( 242,021 ) ( 58,443 ) Present value of lease liabilities $ 3,285,172 $ 688,164 The following are the weighted average assumptions used for lease term and discount rate and supplemental cash flow information related to leases as of June 30, 2023: Operating lease remaining lease term 3.1 years Operating lease discount rate 4.14 % Finance lease remaining lease term 0.8 years Finance lease discount rate 6.69 % Cash paid for operating leases $ 1,449,629 Cash paid for finance leases $ 624,863

Revenue Recognition

Revenue Recognition	12 Months Ended
	Jun. 30, 2023
Revenues [Abstract]
REVENUE RECOGNITION	NOTE 4 - REVENUE RECOGNITION The Company derives its revenue primarily from the sale of seed products to seed distributors. From time to time, the Company utilizes excess capacity to provide conditioning, treating, and packaging services to other seed producers. The Company also derives service revenue from its two partnerships, Trigall Australia and Vision Bioenergy, by providing administrative services under a service level agreement. Revenue from seed product sales is recognized at the point in time at which control of the product is transferred to the customer. Generally, this occurs upon shipment of the product. Pricing for such transactions is negotiated and determined at the time the contracts are signed. We have elected the practical expedient that allows us to account for shipping and handling activities as a fulfillment cost, and we accrue those costs when the related revenue is recognized. The Company has certain contracts with customers that offer a limited right of return on certain branded products through the end of the current sales year (September through August). The products must be in an unopened and undamaged state and must be resalable in the sole opinion of the Company to qualify for a refund. The Company uses a historical returns percentage to estimate the refund liability and records a reduction of revenue in the period in which revenue is recognized. ADAMA Collaboration Agreement The Company has a collaboration agreement, or Collaboration Agreement, with Makhteshim Agan of North America, Inc., or ADAMA, for the development and commercialization of the Double Team TM Sorghum Weed Control System, or DT, which is comprised of ADAMA’s ACCase herbicide used in concert with the Company’s ACCase tolerant ATS Sorghum product, Double Team Sorghum Cropping Solution. Both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. Although the DT product is designed to be used as a system, the Company sells only the Double Team sorghum seed portion of the system and recognizes the revenue consistent with its sales of other seed products. Under the Collaboration Agreement, the Company will only label and promote ATS Sorghum products with ADAMA herbicides, while ADAMA will not sell ACCase herbicides for use on competing ATS Sorghum products. Further, all DT related trademarks are jointly owned by the Company and ADAMA, and each company grants the other a license free royalty to use these DT related trademarks. The parties have agreed to share the increase in commercial value created and realized by DT, or Total Value Share, with the Company and ADAMA taking 60 % and 40 % of the Total Share Value, respectively. The Total Share Value is the sum of (a) the increase in gross margin realized by the Company from sale of the Double Team sorghum product compared to margins realized by its non-ATS Sorghum products, (b) 100 % of the ADAMA’s ACCase herbicide margin, and (c) any DT-related technology licensing fees received by either party. The Total Value Share is estimated each calendar quarter and a final net settlement is paid at the end of each market year, which ends in August. Estimated and final net settlement amounts to be paid or received are recorded as adjustments to cost of sales. Double Team sorghum seed sales were $ 6.5 million and $ 2.4 million for the years ended June 30, 2023 and 2022. The Total Value Share net settlement amount pursuant to the Collaboration Agreement was $ 0.5 million due to ADAMA for the year ended June 30, 2023. The Total Value Share net settlement amount was not significant for the year ended June 30, 2022. Disaggregation of Revenue The Company disaggregates revenue by type of contract and by destination country. The following table shows revenue from external sources by type of contract: Years Ended June 30, 2023 2022 Seed sales $ 72,808,112 $ 69,425,407 Services 713,179 1,928,891 Total revenue $ 73,521,291 $ 71,354,298 Payment Terms and Related Balance Sheet Accounts Accounts receivable repr esent amounts that are payable to the Company by its customers subject only to the passage of time. Payment terms on invoices are generally 30 to 180 days for export customers and end of sales season (October 31 st ) for branded products sold within the United States. As the period between the transfer of goods and/or services to the customer and receipt of payment is less than one year , the Company does not separately account for a financing component in its contracts with customers. The Company had $ 203,222 in unbilled receivables as of June 30, 2023, which largely related to its service level agreement with Vision Bioenergy, as the Company bills Vision Bioenergy on a quarterly basis. The Company had no unbilled receivables as of June 30, 2022. Losses on accou nts receivable and unbilled receivables are recognized if and when it becomes probable that amounts will not be paid. These losses are reversed in subsequent periods if these amounts are paid. During the years ended June 30, 2023 and 2022, the Company recognized bad debt expense of $ 11,659 and $ 216,466 , respectively, associated with impaired accounts receivable. Deferred revenue represents payments received from customers in advance of completion of the Company's performance obligation. During the year ended June 30, 2023, the Company recognized $ 0.6 million o f revenue that was included in the deferred balance as of June 30, 2022. During the year ended June 30, 2022, the Company recognized $ 0.3 million of revenue that was included in the deferred balance as of June 30, 2021.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	NOTE 5 - GOODWILL AND INTANGIBLE ASSETS Goodwill The Company acquired Pasture Genetics in February 2020, and recorded goodwill of $ 1,452,436 as part of this transaction. During the fourth quarter of the fiscal year ended June 30, 2022, the Company had a sustained decline in market valuation of its common stock, thereby triggering a potential indicator of goodwill impairment. As a result, the Company initiated a goodwill impairment test for the year ended June 30, 2022. The Company compared the carrying value of its invested capital to estimated fair values at June 30, 2022. The Company estimated the fair value using the market approach and a control premium (based on management’s best estimate) was added. Upon completing the impairment test, the Company determined that the estimated fair value of invested capital was less than the carrying value, thus indicating an impairment. The Company recognized a goodwill impairment charge of $ 1.5 million for the year ended June 30, 2022, which represented the entire goodwill balance prior to the impairment charge. The Company did no t record any goodwill for the year ended June 30, 2023. The following table summarizes the activity of goodwill for the year ended June 30, 2022: Balance at Additions Impairment Currency Translation Adjustment Balance at Goodwill $ 1,651,634 $ — $ ( 1,548,324 ) $ ( 103,310 ) $ — Intangible Assets Intangible assets consist of the following: Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Intellectual property $ 23,035,925 $ — $ ( 1,385,391 ) $ — $ 21,650,534 Trade name 1,084,791 - ( 196,627 ) ( 7,231 ) 880,933 Customer relationships 5,499,815 — ( 353,000 ) ( 178,140 ) 4,968,675 GI customer list 42,983 — ( 7,164 ) — 35,819 Supply agreement 775,241 — ( 75,633 ) — 699,608 Grower relationships 1,331,581 — ( 105,406 ) — 1,226,175 License agreement 1,986,598 ( 1,885,907 ) ( 75,610 ) ( 25,081 ) — Internal use software 338,893 — ( 67,778 ) — 271,115 $ 34,095,827 $ ( 1,885,907 ) $ ( 2,266,609 ) $ ( 210,452 ) $ 29,732,859 Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Intellectual property $ 24,427,857 $ — $ ( 1,391,932 ) $ — $ 23,035,925 Trade name 1,310,489 - ( 203,009 ) ( 22,689 ) 1,084,791 Customer relationships 6,302,591 — ( 373,393 ) ( 429,383 ) 5,499,815 Non-compete 5,058 — ( 5,058 ) — — GI customer list 50,146 — ( 7,163 ) — 42,983 Supply agreement 850,874 — ( 75,633 ) — 775,241 Grower relationships 1,436,988 — ( 105,407 ) — 1,331,581 License agreement 2,340,269 — ( 172,004 ) ( 181,667 ) 1,986,598 Internal use software 406,670 — ( 67,777 ) — 338,893 $ 37,130,942 $ — $ ( 2,401,376 ) $ ( 633,739 ) $ 34,095,827 Amortization expense totale d $ 2,266,609 and $ 2,401,376 for the years ended June 30, 2023 and 2022, respectively. Estimated aggregate remaining amortization is as follows: 2024 2025 2026 2027 2028 Thereafter Amortization expense $ 2,179,262 $ 2,139,453 $ 2,025,950 $ 1,921,799 $ 1,864,508 $ 19,601,887 For the years ended June 30, 2023 and 2022, the Company determined there was no impairment of its intangible assets.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 6 - PROPERTY, PLANT AND EQUIPMENT Components of property, plant and equipment were as follows: As of As of June 30, 2023 June 30, 2022 Land and improvements $ 939,089 $ 2,265,087 Buildings and improvements 3,356,755 8,119,960 Machinery and equipment 12,667,858 14,972,462 Vehicles 605,891 1,085,342 Leasehold improvements 552,810 552,810 Construction in progress 177,538 110,107 Total property, plant and equipment 18,299,941 27,105,768 Less: accumulated depreciation ( 8,217,773 ) ( 10,234,099 ) Property, plant and equipment, net $ 10,082,168 $ 16,871,669 Depreciation expense total ed $ 1,997,118 an d $ 2,433,319 for the years ended June 30, 2023 and 2022, respectively. AgAmerica Mortgage On June 20, 2023, the Company entered into a Term Loan Agreement with AgAmerica Lending LLC, a Florida limited liability company, or AgAmerica, pursuant to which AgAmerica extended a term loan of $ 4.3 million to the Company and, as security therefor, the Company granted to AgAmerica a mortgage on approximately 31 acres of land located in Lubbock and Moore Counties, Texas, and certain personal property thereon. For further information on the loan, refer to Note 8.

Investments

Investments	12 Months Ended
	Jun. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Investments	NOTE 7 - Investments Shell Partnership On February 6, 2023, or Closing Date, the Company and Shell entered into a Contribution and Membership Interest Purchase Agreement, or Purchase Agreement, relating to a partnership for the development and production of sustainable biofuel feedstocks through its newly created subsidiary Vision Bioenergy Oilseeds LLC, or Vision Bioenergy, pursuant to which: • The Company (i) contributed its Nampa, Idaho production and research facilities, or the Nampa Facilities, to Vision Bioenergy, along with certain personal property, including vehicles, fixed assets and other similar equipment; (ii) caused Vision Bioenergy to make offers of employment to certain key personnel; (iii) assigned to Vision Bioenergy certain contracts and permits; and (iv) agreed to a two-year non-solicitation covenant with respect to the personnel transferred to Vision Bioenergy. • On the Closing Date, Shell (i) made a $ 13.2 million cash contribution to Vision Bioenergy; (ii) paid $ 7.0 million to the Company; and (iii) paid $ 6.9 million to retire in full the principal, accrued interest and related settlement costs of the Rooster Note, which was secured by a priority security interest in the property, plant and fixtures located at the Nampa Facilities. • In February 2024, Shell will be required to pay an additional $ 6.0 million to the Company, subject to adjustment in certain circumstances. The Purchase Agreement provides that this required payment could be decreased by up to $ 4.5 million if (i) the effective employment date of the certain key personnel transferred to Vision Bioenergy, or Transferred Personnel, is later than May 7, 2023, or any of the Transferred Personnel are no longer employed by Vision Bioenergy after February 6, 2024 and (ii) the Company or Vision Bioenergy, as applicable, fail to replace such Transferred Personnel with personnel of reasonably similar qualifications within 90 days of the events covered in clause (i) above. The Company’s management deemed that the full $ 6.0 million payment from Shell to the Company was realizable due to the high likelihood that the key employees would remain employed for the first year, or in any event could be replaced within 90 days. The fair value of the full amount of this payment, based on the discounted value of the payment as of June 30, 2023, was $ 5.8 million, which was recorded to Notes receivable, net on the consolidated balance sheets. • In February 2024, Shell will be required to make an additional $ 12.0 million cash contribution to Vision Bioenergy. The fair value of this February 2024 payment as of June 30, 2023, based on the discounted value of the payment at Shell's incremental borrowing rate, was $ 11.7 million. • S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership tran saction, to purchase a 6 % membership interest from Shell for a purchase price ranging between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The fair market value of the Purchase Option on the Closing Date was $ 0.7 million based on a third party appraisal. • Upon the achievement of certain specified milestones, measured as of the fourth and seventh anniversaries of the closing of the partnership transaction, the Company is eligible to receive transfers of up to an additional aggregate 10 % interest in Vision Bioenergy from Shell, or Contingent Transfers. The basis for recognition and measurement of contingent consideration in deconsolidation is not addressed in ASC 810. The Company has made an accounting policy election to account for these contingent consideration items by analogy to the treatment of property and casualty losses under ASC 610-30, in which anticipated insurance recoveries are limited to the lesser of (1) the amount of proceeds for which the likelihood of receipt is probable or (2) the total loss recognized. Under this approach, if the consideration received in the deconsolidation, excluding the contingent consideration, is greater than the carrying amount of the deconsolidated net assets, no contingent consideration would be recognized initially. Since the consideration received by the Company in sale of the interest in Vision Bioenergy to Shell was greater than the carrying value of the assets deconsolidated, no contingent consideration was recorded by the Company. Subsequent recognition and measurement of the contingent consideration will be made using the gain contingency model set forth in ASC 450-30. Although no contingent assets were recorded by the Company, the Contingent Transfers were a material part of the Purchase Agreement negotiated by the parties and therefore were included in the valuation of Shell’s investment of Vision Bioenergy. The fair value of the Contingent Transfers was determined to be $0 .5 million based on Monte Carlo analysis of management projections of free cash flows. The aggregate total value of the Shell’s payments to the Company and cash contributions to Vision Bioenergy on the Closing Date, the present value of Shell’s future cash payments and contributions, and the fair market values of the Purchase Option and Contingent Transfers, was $ 45.4 million. For this investment, Shell received a 66 % interest in Vision Bioenergy, while the Company retained a 34 % interest. Prior to the closing of the Purchase Agreement, the Vision Bioenergy subsidiary of the Company held production and other property, rights to certain proprietary seed varieties and other trade secrets, and an experienced workforce with the necessary skills, knowledge, or experience to perform a process on the inputs that could generate an output, that meet the definition of a business as defined by ASC 805-10. Accordingly, the transfer of the 66 % interest in Vision Bioenergy to Shell was accounted for as a sale of a business under ASC 805. Concurrent with the sale of the 66 % interest, Vision Bioenergy was deconsolidated from the Company’s books, and the retained interest was recorded as an investment. Shell’s $ 45.4 million investment for a 66 % interest reflected a total valuation of the Vision Bioenergy business of $ 68.8 million. The consideration received by the Company for Shell’s 66 % interest in Vision Bioenergy comprises the $ 7.0 million paid to the Company at closing, the retirement of $ 6.9 million of Company debt, the $ 5.7 million present value of the future payment to the Company at the Closing Date, the $ 0.7 million fair market value of the Purchase Option, and the $ 23.4 million value of the equity investment, or $ 43.7 million in total. The total consideration, less the $ 5.5 million carrying value of the Nampa facility assets and inventory contributed by the Company to Vision Bioenergy, resulted in a gain on the sale in the amount of $ 38.2 million. The gain is reported as Gain on equity method investments on the consolidated statements of operations. This consideration is summarized below: Amount Received (Contributed) Equity investment $ 23,396,832 Cash 7,000,000 Debt retirement 6,860,838 Notes receivable, net 5,747,126 Fair value of 6 % member purchase option 695,000 Fixed assets and inventory transfer ( 5,532,694 ) Gain on equity method investments $ 38,167,102 Vision Bioenergy’s five-member Board of Directors includes two directors designated by the Company. Through its Board representation and 34 % of the voting rights, the Company has significant influence in the management of Vision Bioenergy. Accordingly, the Company’s investment is accounted for using the equity method and reported withi n Equity method investments on the consolidated balance sheets. The Company recognizes its proportionate share of the reported earnings or losses of Vision Bioenergy through net income and as an adjustment to the investment balance. This proportionate share is subject to adjustments, such as for the elimination of intra-entity (intercompany) gains or losses or amortization of basis differences. Vision Bioenergy is a pass-through entity for income tax purposes, with income or loss distributed to the partners. The fair market values of the assets contributed to Vision Bioenergy by the Company at the Closing Date were determined by third-party market appraisals. The Nampa Facilities and other property with an aggregate carrying amount of $ 5.5 million were valued at $ 12.9 million. Rights established under a product uptake agreement with Shell and rights to certain proprietary seed technology with no carrying value on the Company's books, were initially valued at $ 19.2 million. These intangible assets were recorded on Vision Bioenergy's opening balance sheet and will be amortized through the end of their useful life. The net book value of these assets as of June 30, 2023 was $ 18.6 million. The total gain on the sale of the Vision Bioenergy interest recognized by the Company included $ 8.0 million related to the remeasurement of the retained investment in Vision Bioenergy to its fair value. On the Closing Date, the Company's proportionate 34 % share o f Vision Bioenergy’s equity was $ 23.4 million, calculated from the total valuation of the Vision Bioenergy business of $ 68.8 million. Of this, the Company’s equity share of Vision Bioenergy’s net ide ntifiable assets was $ 19.3 million. The $ 4.1 million difference between the carrying amount of the equity method investment and the Company’s share of the net identifiable assets represented equity method goodwill. The equity method goodwill will not be subject to amortization but will assessed for impairment at least annually, or when certain triggering events occur, using fair value measurement techniques. The summarized unaudited balance sheet presented below reflects the financial infor mation of Vision Bioenergy as of June 30, 2023: As of June 30, 2023 (Unaudited) Cash $ 8,973,896 Other current assets 747,090 Fixed assets 15,051,799 Intangible assets 18,575,108 Goodwill 11,870,376 Other assets 255,899 TOTAL ASSETS $ 55,474,168 Current liabilities 1,381,493 Long-term liabilities 176,203 Equity 53,916,472 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 55,474,168 The summarized unaudited income statement presented below reflects the financial information of Vision Bioenergy for the period from February 6, 2023 (inception) through June 30, 2023: Year Ended June 30, 2023 (Unaudited) Revenue $ 168,977 Gross profit (loss) ( 726,502 ) Loss from operations ( 3,358,348 ) Net loss ( 3,203,958 ) Effective February 6, 2023, the Company entered into a service-level agreement, or SLA, with Vision Bioenergy. Pursuant to the SLA, the Company is to provide Vision Bioenergy with services for various functions, including Human Resources, Finance, Accounting, Information Technology, Research, Engineering, and Sales & Marketing. The SLA will terminate on the third anniversary of the effective date; however, it does include an extension option. During the period from February 6, 2023 (inception) through June 30, 2023, the Company recognized $ 0.3 million in service revenue related to this agreement. Concurrent with the SLA, the Company entered into a one-year service agreement with Vision Bioenergy, for which Vision Bioenergy will provide the Company with grain processing services at its Nampa, Idaho facility. The Company has the right to extend the contract for a second year. During the period from Februar y 6, 2023 (inception) through June 30, 2023, the Company paid $ 0.2 million to Vision Bioenergy for services per this agreement. Trigall Australia Partnership Effective December 23, 2022, the Company’s wholly owned subsidiary, S&W Seed Company Australia Pty Ltd, or S&W Australia, entered into a partnership with Trigall Genetics S.A., or Trigall, for the development and marketing of wheat varieties in Australia. Under the terms of the partnership agreement, S&W Australia transferred certain intellectual property license rights and equipment into a wholly owned subsidiary and subsequently sold an 80 % interest in the subsidiary to Trigall. The subsidiary was renamed Trigall Australia Pty Ltd, or Trigall Australia. In return, S&W Australia received $ 2.0 million in cash, a $ 1.0 million promissory note to be paid in December 2023, and retained a 20 % ownership interest in Trigall Australia. The $ 1.0 million promissory note is reported within Notes receivable, net in the consolidated balance sh eets. The $ 3.0 million investment by Trigall for an 80 % interest in Trigall Australia implied a $ 3.8 million valuation. S&W Australia’s 20 % retained interest, valued accordingly at $ 0.8 million, as of the transaction date, is reported as Equity method investments in the consolidated balance sheets. Management determined that the assets transferred to Trigall Australia did not meet the definition of a business for accounting purposes, and the sale was accounted for as an asset sale. The $ 3.8 million valuation, less the $ 2.0 million carrying value of assets contributed, resulted in a $ 1.8 million gain on the sale. The gain is reported as Gain on equity method investment on the consolidated statements of operations. The Company recognizes its proportionate share of the reported earnings or losses of Trigall, net of tax, through net income and as an adjustment to the investment balance. S&W Australia is obligated to make an aggregate of $ 0.6 million in capital contributions to Trigall Australia through June 2025, and has agreed to provide certain marketing, collection and other operational services in support of the partnership. For the year ended June 30, 2023, the Company made $ 0.2 million in capital contributions. Bioceres Investment As of June 30, 2021, the Company held an investment in Bioceres, S.A., a provider of crop productivity solutions headquartered in Argentina. During the third quarter of fiscal year 2022, the Company sold 71.4 % of the investment in Bioceres, S.A. for net proceeds of $ 1.0 million, which included a gain on the sale of marketable securities of $ 0.1 million. The carrying value of the remainder of the investment was $ 0.4 million at June 30, 2022, which was reported in Equity method investments on the Company's consolidated balance sheets. During the year ended June 30, 2023, the Company sold off the remainder of its investment in Bioceres, S.A. for net proceeds of $ 0.4 million, which included a gain on the sale of equity investment of $ 32,030 . The following summarizes the carrying amount of the Company's equity method investments reflected in the consolidated balance sheets: June 30, 2023 June 30, 2022 Carrying Amount Economic Interest Carrying Amount Economic Interest Vision Bioenergy $ 22,307,486 34 % $ — 0 % Trigall Australia 752,219 20 % — 0 % Bioceres — 0 % 367,970 1 % Total equity method investments $ 23,059,705 $ 367,970

Debt

Debt	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
DEBT	NOTE 8 - DEBT Total debt outstanding is presented on the consolidated balance sheets as follows: June 30, 2023 June 30, 2022 Current portion of working capital lines of credit CIBC $ 19,335,427 $ 12,804,611 National Australia Bank Limited 25,938,839 338,314 Debt issuance costs ( 373,487 ) ( 464,028 ) Total current portion of working capital lines of credit, net 44,900,779 12,678,897 Long-term portion of working capital lines of credit, less current portion National Australia Bank Limited — 21,703,286 Total working capital lines of credit, net $ 44,900,779 $ 34,382,183 Current portion of long-term debt Finance leases $ 383,403 $ 804,309 Term Loan - National Australia Bank Limited 2,318,050 344,400 Machinery & equipment loans - National Australia Bank Limited 1,141,349 246,547 Machinery & equipment loans - Hyster 11,902 11,834 Vehicle loans - Ford Credit 51,278 40,341 Secured real estate note - Rooster — 6,905,995 Debt issuance costs ( 97,221 ) ( 36,643 ) Total current portion, net 3,808,761 8,316,783 Long-term debt, less current portion Finance leases 304,761 500,723 Term loan - National Australia Bank Limited — 2,410,800 Machinery & equipment loans - National Australia Bank Limited — 963,733 Machinery & equipment loans - Hyster 15,715 28,722 Vehicle loans - Ford Credit 70,103 88,583 Secured real estate note - AgAmerica 4,300,000 — Debt issuance costs ( 191,245 ) ( 21 ) Total long-term portion, net 4,499,334 3,992,540 Total debt, net $ 8,308,095 $ 12,309,323 CIBC Loan Agreement On December 26, 2019 , the Company entered into a Loan and Security Agreement, or the Loan Agreement, with CIBC, which originally provided for a $ 35.0 million credit facility, or the CIBC Credit Facility. The Loan Agreement was subsequently amended on several occasions in fiscal 2022 and again in fiscal 2023. During the year ended June 30, 2023, the CIBC Loan Agreement was amended as follows: • On September 22, 2022, the CIBC Loan Agreement was amended to, among other things, (i) specify that the borrowing base eligible inventory sublimit cannot be reduced below the proceeds available to be drawn under the MFP Letter of Credit (as defined below), (ii) waive the Company's non-compliance with certain financial covenants under the CIBC Loan Agreement and (iii) establish a minimum liquidity of no less than $ 1.0 million tested weekly as of the last day of each week for the remainder of the term of the CIBC Loan Agreement; • On October 28, 2022, the CIBC Loan Agreement was amended to, among other things, increase (i) the total revolving loan commitment to $ 21.0 million from $ 18.0 million and (ii) the borrowing base eligible inventory sublimit to $ 12.0 million from $ 9.0 million; • On December 23, 2022, the CIBC Loan Agreement was amended to, among other things, extend the maturity date of all revolving loans, advances and other obligations outstanding under the CIBC Loan Agreement from December 23, 2022 to March 23, 2023 ; and • On March 22, 2023, the Company entered into an Amended and Restated Loan and Security Agreement, or the Amended CIBC Loan Agreement, with CIBC, as administrative agent and sole lead arranger, and the other loan parties and lenders party thereto. The Amended CIBC Loan Agreement replaced the existing CIBC Loan Agreement. All amounts outstanding under the Amended CIBC Loan Agreement, including, but not limited to, accrued and unpaid principal and interest due under the CIBC Credit Facility, will be due and payable in full on August 31, 2024 . The following is a summary of certain terms of the Amended CIBC Credit Facility as of June 30, 2023: • The Amended CIBC Loan Agreement provides up to $ 25.0 million credit facility from February 1 to October 31 of each year and up to a $ 18.0 million credit facil ity from November 1 to January 31 of each year. • Advances under the Amended CIBC Credit Facility are to be used: (i) to finance the Company’s ongoing working capital requirements; and (ii) for general corporate purposes. • Availability of funds under the Amended CIBC Credit Facility is subject to a borrowing base of up to 85 % of eligible domestic accounts receivable ( 90 % of eligible foreign accounts receivable) plus up to the lesser of (i) 65 % of eligible inventory, (ii) 85 % of the appraised net orderly liquidation value of eligible inventory , and (iii) an eligible inventory sublimit as more fully set forth in the Loan Agreement, in each case, subject to lender reserves. • Advances bear interest at a rate per annum equal to a reference rate equal to CIBC's prime rate at any time (or, if greater, the federal funds rate at such time plus 0.5 %) plus an applicable margin of 2.0 %. The interest rate was 10.25 % as of June 30, 2023. Additionally, upon the occurrence and during the continuance of an event of default, CIBC may elect to increase the existing interest rate on all of the Company's outstanding obligations by 2.0 % per annum. • The Amended CIBC Credit Facility is secured by a first priority perfected security interest in substantially all of the Borrowers’ assets (subject to certain exceptions), including intellectual property. • The Amended CIBC Loan Agreement contains certain customary representations and warranties, events of default, and affirmative and negative covenants, including limitations with respect to debt, liens, fundamental changes, asset sales, restricted payments, investments and transactions with affiliates, subject to certain exceptions. The CIBC Loan Agreement restricts the payment of dividends. Amounts due under the Amended CIBC Loan Agreement may be accelerated upon an “event of default,” as defined in the Amended CIBC Loan Agreement, such as failure to pay amounts owed thereunder when due, breach of a covenant, material inaccuracy of a representation, or occurrence of bankruptcy or insolvency, subject in some cases to cure periods. The Company actively pursued multiple other lenders prior to entering into the Amended CIBC Loan Agreement on March 22, 2023. The financing charges incurred associated with these other lenders totaled $ 1.5 million and were exp ensed to Other (income) expenses in the consolidated statements of operations. As of June 30, 2023, the Company was not in compliance with the debt covenant of the Amended CIBC Loan Agreement that required the Company to meet a certain minimum adjusted EBITDA level at year-end. A waiver was obtained from CIBC for this failed covenant. As of June 30, 2023, there wa s approximately $ 0.8 million of unused availability on the Amended CIBC Credit Facility, which had an available borrowing base of $ 20.2 million. With additional collateral consisting of accounts receivable, the available borrowing base can increase by an additional $ 4.8 million, to a maximum amount of $ 25.0 million. Australian Facilities S&W Australia has debt facilities with NAB. The financing agreement with NAB, or the NAB Finance Agreement, which provides a term loan, a master asset finance facility, and a seasonal credit facility that includes a borrowing base line and an overdraft facility used to finance the purchase of seed inventory from growers. The NAB Finance Agreement was amended and restated effective October 24, 2022 and further amended on October 25, 2022. Pursuant to the amendments contained in the NAB Finance Agreement, among other things: • the borrowing base line credit limit under S&W Australia’s seasonal credit facility was increased from AUD $ 32.0 million (USD $ 21.2 million as of June 30, 2023) to AUD $ 40.0 million (USD $ 26.5 million as of June 30, 2023), with a one-year maturity date extension to September 30, 2024 ; • the overdraft credit limit under S&W Australia’s seasonal credit facility was increased from AUD $ 1.0 million (USD $ 0.7 million as of June 30, 2023) to AUD $ 2.0 million (USD $ 1.3 million as of June 30, 2023), with a one-year maturity date extension to September 29, 2023 ; and • the maturity date of S&W Australia’s master asset finance facility was extended by one year to September 29, 2023 . As amended, the consolidated debt facilities under the NAB Finance Agreement provide for up to an aggregate of AUD $ 49.0 million (USD $ 32.5 million as of June 30, 2023) of credit and is guaranteed by S&W Seed Company up to a maximum of AUD $ 15.0 million (USD $ 9.9 million as of June 30, 2023). The financing facilities include the following elements as of June 30, 2023: • A Seasonal Credit Facility comprised of two facility lines: (i) a Borrowing Base Line having a credit limit of AUD $ 40.0 million (USD $ 26.5 million as of June 30, 2023) and (ii) an Overdraft Facility having a credit limit of AUD $ 2.0 million (USD $ 1.3 million at June 30, 2023). The interest rate for a drawing denominated in a foreign currency is fixed at the time of drawing and will be the foreign currency fixed lending rate plus a customer margin of 1.65 % per annum. As of June 30, 2023, the Borrowing Base Line accrued interest on Australian dollar drawings at 8.21 % per annum calculated daily. The Overdraft Facility permits S&W Australia to borrow funds on a revolving line of credit up to the credit limit. Interest accrues daily and is calculated by applying the daily interest rate to the balance owing at the end of the day and is payable monthly in arrears. As of June 30, 2023, the Overdraft Facility accrued interest at 9.47 % per annum calculated daily. The Seasonal Credit Facility is secured by a fixed and floating lien over all the present and future rights, property, and undertakings of S&W Australia. As o f June 30, 2023, approximately AUD $ 0.3 million (USD $ 0.2 million) remained available for use under the NAB Finance Agreement, which had an available borrowing base of AUD $ 39.4 million (USD $ 26.1 million). With additional collateral, the available borrowing base can increase by an additional AUD $ 2.6 million (USD $ 1.7 million as of June 30, 2023), to a maximum amo unt of AUD $ 42.0 million (USD $ 27.8 million as of June 30, 2023). • A flexible rate loan, or the Term Loan, in the am ount of AUD $ 4.0 million (USD $ 2.6 million at June 30, 2023). Required annual principal payments of AUD $ 0.5 million on the Term Loan commenced in May 2023 , with the remainder of any unpaid balance becoming due on March 31, 2026 . Monthly interest amounts outstanding under the Term Loan are payable in arrears at a floating rate quoted by NAB for the applicable pricing period, plus 2.6 %. The interest rate as of June 30, 2023 for this was 8.607 %. The Term Loan is secured by a lien on all the present and future rights, property and undertakings of S&W Australia. • S&W Australia finances certain equipment purchases under a master asset finance facility with NAB. Equi pment loans under the master asset finance facility have various maturity dates through 2029 , which have interest rates ranging from 2.86 % to 6.82 %. The total credit limit under the facility is AUD $ 3.0 million (USD $ 2.0 million at June 30, 2023). As of June 30, 2023, AUD $ 1.7 million (USD $ 1.1 million) was outstanding under S&W Australia’s master asset finance facility. The October 2022 amendments to the NAB Finance Agreement contained an undertaking requiring the Company to maintain a net related entity position of not more than AUD $ 25.0 million, and the Company's ability to comply with this undertaking was subject to fluctuations in foreign currency conversion rates outside of the Company's control. Due to fluctuations in foreign currency conversion rates, the Company was not in compliance with this undertaking as of December 31, 2022 and the Company subsequently obtained a waiver from NAB with respect to such non-compliance. On January 11, 2023, the Company further amended the NAB Finance Agreement to change the required net related entity position from AUD $ 25.0 million to USD $ 18.5 million. The Company believes that this amendment provides the Company with greater control over compliance with this undertaking. The Company was in compliance with this covenant as of March 31, 2023 and June 30, 2023. The Company was not in compliance with the annual interest cover ratio covenant as of June 30, 2023, but obtained a waiver from NAB with respect to such non-compliance. AgAmerica Note On June 20, 2023 , the Company entered into a term loan agreement, or the AgAmerica Loan Agreement, with AgAmerica pursuant to which AgAmerica issued a term loan of $ 4.3 million, or the AgAmerica Term Loan, to the Company and, as security therefor, the Company granted to AgAmerica a mortgage on approximately 31 acres of land located in Lubbock and Moore Counties, Texas, and certain personal property thereon. The AgAmerica Term Loan is evidenced by a Promissory Note, or the AgAmerica Note, issued by the Company to AgAmerica, pursuant to which the Company agreed to pay AgAmerica the principal sum of $ 4.3 million, plus any outstanding accrued interest thereon, in full on June 20, 2026 , unless otherwise accelerated in accordance with the terms of the AgAmerica Loan Agreement and the AgAmerica Note. Interest will accrue at a rate per annum equal to 4.85 % plus the Term SOFR Rate, defined as the forward-looking term rate based on the secured overnight financing rate, or SOFR, computed based on the actual number of days elapsed divided by a 360-day year. The annual interest rate as of June 30, 2023 was 9.94 %. Interest payments are due quarterly in arrears, commencing on June 20, 2023, and on the last day of each quarter thereafter, unless otherwise accelerated in accordance with the terms of the AgAmerica Loan Agreement or the AgAmerica Note. AgAmerica may collect a late charge of 5.0 % of any installment of principal or interest which is not paid within 10 days of the due date thereof. In addition, any delinquent principal and installments of interest not paid within 30 days of the due date thereof will bear interest beginning on the 31st day from the applicable due date at a rate equal to 5.0 % per annum above the interest rate. The Company may prepay the AgAmerica Term Loan prior to maturity, subject to a prepayment premium equal to 1.0 % of the prepaid principal amount, subject to certain exceptions. The AgAmerica Loan Agreement contains certain customary representations and warranties, events of default, and affirmative and negative covenants, including (among others) limitations with respect to liens, fundamental changes, asset sales and formation and acquisition of subsidiaries, subject to certain exceptions. Upon the occurrence of an event of default, and subject to certain cure periods, AgAmerica may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the AgAmerica Loan Agreement and the AgAmerica Note, as applicable, provided that in the event of bankruptcy, all such amounts shall automatically become due and payable. Rooster Note In November 2017, the Comp any entered into a secured note financing transaction, or the Loan Transaction, with Conterra Agricultural Capital, LLC, or Conterra, for $ 12.5 million in gross proceeds. Pursuant to the Loan Transaction, the Company issued secured notes to Conterra in the principal amounts of $ 2.1 million, which was repaid in full in fiscal 2019. The Company also issued to Conterra a secured note of $ 10.4 million, which was subsequently endorsed to Rooster Capital LLC, or the Rooster Note. The Rooster Note bore interest at 7.75 % per annum and was secured by a first priority security interest in the property, plant and fixtures located at the Company's Nampa, Idaho produc tion and research facilities. Through June 30, 2021, the Company made payments in reduction of the principal balance totaling approximately $ 3.1 million, and further principal payments of $ 0.4 million and $ 0.4 million during the year ended June 30, 2022 and the six months ended December 31, 2022, respectively. During the year ended June 30, 2023, the Rooster Note was amended as follows: • on September 22, 2022, the Company entered into an amendment to extend the Rooster Note’s maturity date to December 23, 2022 ; and • on December 23, 2022, the Company entered into an amendment to the Rooster Note that (i) increased the interest rate on the Rooster Note from 7.75 % to 9.25 % per annum and (ii) extended the maturity date of the Rooster Note from December 23, 2022 to March 1, 2023 . On February 6, 2023, Shell paid off the approximately $ 6.6 million of outstanding principal and accrued interest on the Rooster Note in connection with the Vision Bioenergy partnership (see Note 7). MFP Loan Agreement On September 22, 2022, the Company’s largest stockholder, MFP Partners, L.P., or MFP, provided a letter of credit issued by JPMorgan Chase Bank, N.A. for the account of MFP, with an initial face amount of $ 9.0 million, or the MFP Letter of Credit, for the benefit of CIBC, as additional collateral to support the Company’s obligations under the CIBC Loan Agreement. The MFP Letter of Credit initially matured on January 23, 2023 , one month after the maturity date of the existing CIBC Loan Agreement. Concurrently, on September 22, 2022, the Company entered into a Subordinate Loan and Security Agreement, or the MFP Loan Agreement, with MFP, pursuant to which any draw CIBC may make on the MFP Letter of Credit will be deemed to be a term loan advance made by MFP to the Company. The MFP Loan Agreement initially provided for up to $ 9.0 million of term loan advances. Concurrent with the October 28, 2022, amendment to the CIBC Loan Agreement (as described above), MFP amended the MFP Letter of Credit to increase the face amount from $ 9.0 million to $ 12.0 million, and the MFP Loan Agreement was amended to increase the maximum amount of term loan advances available to the Company from $ 9.0 million to $ 12.0 million. In connection with the December 23, 2022 amendment to the CIBC Loan Agreement, MFP amended the MFP Letter of Credit, extending the maturity date from January 23, 2 023 to April 30, 2023 . In connection with the Company’s entry into the Amended CIBC Loan Agreement, MFP further amended letter of credit to increase the maximum amount of term loan advances to $ 13.0 million and extend the maturity date to September 30, 2024 . As amended, the MFP Loan Agreement will mature on March 30, 2025 . Pursuant to the MFP Loan Agreement, the Company accrued a cash fee to be paid to MFP equal to 3.50 % per annum on all amounts remaining undrawn under the MFP Letter of Credit. In the event any term advances are deemed made under the MFP Loan Agreement, such advances will bear interest at a rate per annum equal to term SOFR (with a floor of 1.25 %) plus 9.25 %, 50 % of which will be payable in cash on the last day of each fiscal quarter and 50 % of which will accrue as payment in kind interest payable on the maturity date, unless, with respect to any quarterly payment date, the Company elects to pay such interest in cash. Concurrent with the March 22, 2023 amendment to the CIBC Loan Agreement, the Company entered into a Third Amendment to Subordinate Loan and Security Agreement with MFP, or MFP Amendment, to (i) increase the aggregate amount of cash advances permitted from $ 12.0 million to $ 13.0 million; (ii) increase the cash fee payable to MFP on all amounts remaining undrawn under the Letter of Credit from 3.50 % to 4.25 % per annum; (iii) provide for the issuance of the MFP Warrant to MFP (see Note 9); and (iv) reflect the extension of the maturity date of the Letter of Credit to September 30, 2024 . The MFP Loan Agreement, as amended, includes customary affirmative and negative covenants and events of default and is secured by substantially all of the Company’s assets and is subordinated to the CIBC Loan Agreement. Upon the occurrence and during the continuance of an event of default, MFP may declare all outstanding obligations under the MFP Loan Agreement immediately due and payable and take such other actions as set forth in the MFP Loan Agreement. Maturities of Long-Term Debt The annual maturities of long-term debt, excluding finance lease liabilities, are as follows: Fiscal Year Amount 2024 $ 3,522,579 2025 75,904 2026 4,309,914 Total $ 7,908,397

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 9 - INCOME TAXES Income (loss) before income taxes consists of the following: Years Ended June 30, 2023 2022 United States $ 20,631,632 $ ( 37,346,576 ) Foreign ( 5,707,581 ) 1,437,493 Income (loss) before income taxes $ 14,924,051 $ ( 35,909,083 ) Significant components of the provision for income taxes from continuing operations are as follows: Years Ended June 30, 2023 2022 Current: State 12,431 301 Foreign 42,480 266,129 Total current provision 54,911 266,430 Deferred: Federal — ( 1 ) Foreign ( 818,550 ) 146,994 Total deferred provision ( 818,550 ) 146,993 Provision for (benefit from) income taxes $ ( 763,639 ) $ 413,423 The differences between the total calculated income tax provision and the expected income tax computed using the U.S. federal income tax rate are as follows: Years Ended June 30, 2023 2022 Tax benefit at statutory tax rate $ 3,134,080 $ ( 7,540,908 ) State benefit, net of federal benefit 388,572 ( 493,262 ) Estimated GILTI Inclusion 267,352 — Federal and state research credits - current year 67,144 ( 390,235 ) Other permanent differences ( 187,808 ) 184,725 Foreign rate differential ( 521,188 ) 420,829 Goodwill impairment — 549,577 Valuation allowance ( 5,371,275 ) 7,573,300 Transfer Pricing Adjustments 1,380,810 — Stock Compensation 266,127 — Equity method investments ( 277,952 ) — Other 90,499 109,397 Provision for (benefit from) income taxes $ ( 763,639 ) $ 413,423 Significant components of the Company's deferred tax assets and liabilities are as follows: 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 21,170,710 $ 22,815,372 Tax credit carryforwards 2,184,461 1,388,106 Allowance for bad debts 1,184,158 1,216,187 Goodwill 1,688,905 1,597,873 Lease liability 880,955 1,187,090 Interest expense carryforwards 1,446,422 1,144,535 Other, net 2,588,490 1,756,460 Total deferred tax assets 31,144,101 31,105,623 Valuation allowance for deferred tax assets ( 22,061,576 ) ( 27,437,845 ) Deferred tax assets, net of valuation allowance 9,082,525 3,667,778 Deferred tax liabilities: ROU lease asset ( 903,508 ) ( 1,226,879 ) Equity method investments ( 4,620,682 ) — Intangible assets ( 1,910,044 ) ( 1,381,955 ) Fixed assets ( 1,160,228 ) ( 1,382,821 ) Total deferred tax liabilities ( 8,594,462 ) ( 3,991,655 ) Net deferred tax asset (liability) $ 488,063 $ ( 323,877 ) The Company recognizes federal and state current tax liabilities or assets based on its estimate of taxes payable to or refundable from tax authorities in the current fiscal year. The Company also recognizes federal and state deferred tax liabilities or assets based on the Company’s estimate of future tax effects attributable to temporary differences and carryforwards. The Company records a valuation allowance to reduce any deferred tax assets by the amount of any tax benefits that, based on available evidence and judgment, are not expected to be realized. In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. The Company considers projected future taxable income and planning strategies in making this assessment. Based on projections of taxable income, the Company had previously determined that it is more likely than not that the deferred tax assets in the United States and South Africa will not be realized. The Company also previously determined that the deferred tax assets related to certain Australian intangible assets more likely than not would not be realized. Accordingly, a valuation allowance was recorded against the net deferred tax assets in the United States and South Africa and a partial valuation allowance was recorded to Australian deferred tax assets. The valuation allowance decreased by approximately $ 5.4 million for the year ended June 30, 2023, related primarily to tax loss carryforwards utilized in the United States in the current year to offset taxable gain related primarily to the Vision Bioenergy transaction. As of June 30, 2023, the Company had federal and state net operating loss carryovers of approximately $ 92.5 million and $ 32.1 million, respectively. Federal net operating losses generated after June 30, 2018 can be carried forward indefinitely, which represented $ 72.8 million of this total. The remaining balance will begin to expire June 30, 2031 , unless utilized. The U.S. Internal Revenue Code of 1986, as amended, generally imposes an annual limitation on a corporation's ability to utilize net operating loss carryovers, or NOLs, if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 % over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization of the Company’s NOLs would be subject to an annual limitation under Section 382 as determined by multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate as defined in the Internal Revenue Code. Any unused annual limitation may be carried over to later years. The Company could experience an ownership change under Section 382 as a result of events in the past in combination with events in the future. If so, the use of the Company’s NOLs, or a portion thereof, against future taxable income may be subject to an annual limitation under Section 382, which may result in expiration of a portion of the NOLs before utilization. To the extent our use of net operating loss carryforwards is significantly limited under the rules of Section 382, our income could be subject to U.S. corporate income tax earlier than it would if we were able to use net operating loss carryforwards, which could result in lower profits. Any carryforwards that expire prior to utilization as a result of such limitations will be removed, if applicable, from deferred tax assets with a corresponding reduction of the valuation allowance. As of June 30, 2023, $ 17.1 millio n of our Federal net operating losses are subject to annual limitations under Section 382. The Company has federal research credits of $ 1.4 million which will expire June 30, 2031 , unless utilized. As of June 30, 2023, the Company has Australian non-refundable research and development credits of $ 0.7 million that can be carried forward indefinitely. The Company also has foreign tax credits of $ 0.2 million which began expiring on June 30, 2023 . The Company has state research credits of $ 25,089 that do not expire. In addition, the Company has $ 6.6 mil lion of Section 163(j) interest limitation carryovers as of June 30, 2023 that can be carried forward indefinitely. As of June 30, 2023, the Company has not provided for foreign withholding and deferred income taxes on approximately $ 2.3 million of undistributed earnings of its foreign subsidiaries, as these earnings are considered indefinitely reinvested outside of the United States. A determination of the unrecognized deferred taxes is not practicable. The Company does not plan to repatriate any earnings that are currently located in its foreign subsidiaries as of June 30, 2023. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company regularly assesses the potential outcome of examinations by tax authorities in determining the adequacy of its provision for income taxes. The following table summarized the activity related to our unrecognized tax benefits: Years Ended June 30, 2023 2022 Beginning Balance $ 77,350 $ 79,341 Other ( 431 ) ( 1,991 ) Ending Balance $ 76,919 $ 77,350 The Company has approximately $ 0.1 million of unrecognized tax benefits related to prior year tax positions as of June 30, 2023. Included in the unrecognized tax benefits was approximately $ 0.1 million of tax benefits that, if recognized, would reduce our annual effective tax rate, if the Company were not in a valuation allowance position. However, due to the valuation allowance in the United States, there would be no impact to the annual effective tax rate if the tax benefits were recognized. The Company's policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. The Company has no t accrued interest and penalties associated with uncertain tax positions as of Ju ne 30, 2023 and 2022. The Company does no t expect its unrecognized tax benefits to change significantly over the next 12 months.

Foreign Currency Contracts

Foreign Currency Contracts	12 Months Ended
	Jun. 30, 2023
Foreign Currency [Abstract]
FOREIGN CURRENCY CONTRACTS	NOTE 10 - FOREIGN CURRENCY CONTRACTS The Company’s subsidiary, S&W Australia, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company manages through the use of foreign currency forward contracts. These foreign currency contracts are not designated as hedging instruments; accordingly, changes in the fair value are recorded in current period earnings. These foreign currency contracts had a notional value of $ 9,561,155 at June 30, 2023 and their maturities range from July 2023 to October 2023 . The Company records an asset or liability on the consolidated balance sheets for the fair value of the foreign currency forward contracts. The foreign currency contract liabilities to taled $ 849,033 and $ 996,106 at June 30, 2023 and 2022, respectively. The Company recorded a gain on foreign exchange contracts of $ 123,703 for the year ended June 30, 2023 and a loss on foreign exchange contracts of $ 958,373 for the year ended June 30, 2022, which are reflected in cost of revenue on the consolidated statements of operations. In June 2023, the Company acquired foreign currency options with a total notional amount of $ 7.4 million. The strike prices on the transaction dates and as of June 30, 2023 were above the market price, so the options had no intrinsic value. Option premiums of $ 5,891 are reflected within Prepaid expenses and other current assets on the consolidated balance sheets as of June 30, 2023. The Company's accounting policies for foreign currency contracts and options are found in Note 2 under the section titled " Derivative Financial Instruments."

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 - COMMITMENTS AND CONTINGENCIES Contingencies Based on information currently available, management is not aware of any other matters that would have a material adverse effect on the Company's financial condition, results of operations or cash flows. Legal Matters The Company may be subject to various legal proceedings from time to time. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote.

Equity

Equity	12 Months Ended
	Jun. 30, 2023
Equity [Abstract]
EQUITY	NOTE 12 - EQUITY ATM Common Stock Sales On September 23, 2020, the Company entered into an At Market Issuance Sales Agreement, or the ATM Agreement, with B. Riley Securities, Inc., or B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, shares of its common stock having an aggregate offering price of up to $ 14.0 million through B. Riley as its sales agent. The Company agreed to pay B. Riley a commission of 3.5 % of the gross proceeds of the sales price per share of any common stock sold through B. Riley under the ATM Agreement. On September 27, 2021, the Company entered into an amendment to the ATM Agreement, under which the aggregate offering price was increased from $ 14.0 million to $ 17.1 million. On May 17, 2022, the Company amended the ATM Agreement to having an aggregate offering price of $ 24.6 million. For the year ended June 30, 2022, the Company received gross proceeds of approximately $ 7.4 million from the sale of 3,655,136 shares of its common stock pursuant to the ATM agreement. For the year ended June 30, 2023, the Company received gross proceeds of approximately $ 0.2 million from the sale of 102,455 shares of its common stock pursuant to the A TM Agreement. As of June 30, 2023, the Company had $ 6.2 million remaining available to sell under the ATM Agreement. MFP Warrants On September 22, 2022, the Company entered into a Subordinate Loan and Security Agreement, or the MFP Loan Agreement, with MFP, pursuant to which any draw CIBC may make on the MFP Letter of Credit will be deemed to be a term loan advance made by MFP to the Company (see Note 8). Pursuant to the terms and conditions of the MFP Loan agreement, on September 22, 2022, the Company issued to MFP a warrant, or Initial Warrant, to purchase up to 500,000 shares of the Company’s common stock, or Initial Warrant Shares, at $ 1.60 per share. The Initial Warrant expires five years from its issue date, or September 22, 2027. In connection with the October 28, 2022 and December 22, 2022 amendments to the MFP Letter of Credit, the Company issued to MFP additional warrants to purchase 166,700 and 666,700 shares of the Company’s common stock, respectively, at an exercise price of $ 1.60 per warrant share. The warrants will each expire five years from the date of issuance. In connection with the MFP Amendment, on March 22, 2023, the Company issued to MFP a warrant to purchase 1,300,000 shares of the Company’s common stock at an exercise price of $ 2.15 per MFP warrant share. The warrants will expire five years from the date of issuance. In total, warrants to purchase 2,633,400 shares of the Company’s common stock were issued to MFP in connection with the MFP Loan Agreement, or MFP Warrants, during the year ended June 30, 2023. The stated purchase prices of all of the MFP Warrants are subject to adjustment in connection with any stock dividends and splits, distributions with respect to common stock and certain fundamental transactions as described in the MFP Warrant. The MFP Warrants were valued using the Black-Scholes-Merton model as of the respective issue dates and recorded as financial commitment assets within Prepaid expenses and other current asset on the consolidated balance sheets. The MFP Warrants financial c ommitment assets are amortized on a straight-line basis over the period from their initial issue dates through the end of the related MFP Letter of Credit commitment periods. During the year ended June 30, 2023, an aggregate value of $ 1,894,901 related to the MFP Warrants was capitalized, of which $ 860,758 was amortized as interest expense. MFP is the Company’s largest shareholder. One of the Company’s directors, Alexander C. Matina, is Vice President and Portfolio Manager of MFP Investors LLC, the general partner of MFP.

Equity-Based Compensation

Equity-Based Compensation	12 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
EQUITY-BASED COMPENSATION	NOTE 13 - EQUITY-BASED COMPENSATION Equity Incentive Plans In October 2009 and January 2010, the Company's Board of Directors and stockholders, respectively, approved the 2009 Equity Incentive Plan, or as amended and/or restated from time to time, the 2009 Plan. The plan authorized the grant and issuance of options, restricted shares and other equity compensation to the Company's directors, employees, officers and consultants, and those of the Company's subsidiaries and parent, if any. In October 2012 and December 2012, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 1,250,000 shares. In September 2013 and December 2013, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 1,700,000 shares. In September 2015 and December 2015, the Company's Board of Directors and stockholders, respectively, approved the amendment and restatement of the 2009 Plan, including an increase in the number of shares available for issuance as grants and awards under the Plan to 2,450,000 shares. In December 2018 and January 2019, the Company's Board of Directors and stockholders, respectively, approved the 2019 Equity Incentive Plan, or the 2019 Plan, as a successor to and continuation of the 2009 Plan. In October 2020 and December 2020, the Company’s Board of Directors and stockholders approved, respectively, the amendment to the 2019 Plan to increase the number of shares available for issues as grants and awards by 4,000,000 shares. Subject to adjustment for certain changes in the Company's capitalization, the aggregate number of shares of the Company's common stock that may be issued under the 2019 Plan, as amended, will not exceed 8,243,790 shares, which is the sum of (i) 4,000,000 new shares, (ii) 2,750,000 additional shares that were reserved as of the effective date of the 2019 Plan, (iii) 350,343 shares (the number of unallocated shares that were available for grant under the 2009 Plan as of January 16, 2019, the effective date of the 2019 Plan), plus (iv) 1,143,447 shares, which is the number of shares subject to outstanding stock awards granted under the 2009 Plan that on or after the effective date of the 2019 Plan may expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise return to us, or are reacquired, withheld or not issued to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award. The term of incentive stock options granted under the Company’s equity incentive plans may not exceed ten years , or five years for incentive stock options granted to an optionee owning more than 10% of the Company's voting stock. The exercise price of options granted under the Company’s equity incentive plans must be equal to or greater than the fair market value of the shares of the common stock on the date the option is granted. An incentive stock option granted to an optionee owning more than 10 % of voting stock must have an exercise price equal to or greater than 110 % of the fair market value of the common stock on the date the option is granted. The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. Stock options issued to non-employees are accounted for at their estimated fair value. The fair value of options granted to non-employees is re-measured as they vest. The Company amortizes stock-based compensation expense on a straight-line basis over the requisite service period. The Company utilizes a Black-Scholes-Merton option pricing model, which includes assumptions regarding the risk-free interest rate, dividend yield, life of the award, volatility of the Company's common stock and estimated forfeiture rates to estimate the fair value of employee option grants. Weighted average assumptions used in the Black-Scholes-Merton model are set forth below: June 30, 2023 2022 Risk free rate 2.9 % - 4.4 % 0.8 % - 2.8 % Dividend yield — — Volatility 64.7 % - 66.1 % 61.7 % - 64.7 % Forfeiture rate 9.1 % 3.2 % Stock Options During the year ended June 30, 2023, the Company granted 1,389,675 options to its directors, certain members of the executive management team and other employees at exercise prices ranging from $ 0.81 - $ 1.89 . These options vest in either quarterly or annual periods over one to three years , and expire ten years from the date of grant. A summary of stock option activity for the years ended June 30, 2023 and 2022 is presented below: Number of Weighted - Weighted- Aggregate Outstanding at June 30, 2021 3,776,568 $ 2.65 8.0 $ 3,962,766 Granted 994,725 2.63 Exercised ( 38,774 ) 2.33 Canceled/forfeited/expired ( 95,419 ) 2.82 Outstanding at June 30, 2022 4,637,100 $ 2.64 6.6 $ — Granted 1,389,675 1.25 Exercised ( 2,100 ) 0.95 Canceled/forfeited/expired ( 947,707 ) 2.84 Outstanding at June 30, 2023 5,076,968 $ 2.23 7.1 $ 292,079 Options vested and exercisable at June 30, 2023 3,685,678 $ 2.47 6.3 $ 59,669 Options vested and expected to vest as of June 30, 2023 5,066,581 $ 2.23 7.1 $ 289,227 The weighted average grant date fair value of options granted and outstanding at June 3 0, 2023 was $ 0.69 . A s of June 30, 2023, the Company had $ 944,925 of unrecognized stock compensation expense, net of estimated forfeitures, related to the options under the 2009 Plan, which will be recognized over the weighted average remaining service pe riod of 1.47 ye ars. The Company settles employee stock option exercises with newly issued shares of common stock. Restricted Stock Units During the years ended June 30, 2023 and 2022, the Company issued 534,628 and 304,421 restricted stock units to its directors, certain members of the executive management team, and other employees. The restricted stock units have varying vesting periods ranging from immediate vesting to quarterly or annual installments over one to three years . The fair value of the awards during the years ended June 30, 2023 and 2022 totaled $ 608,618 and $ 846,080 , respectively, and was based on the closing stock price on the date of grants. The Company recor ded $ 1,932,416 and $ 982,422 of stock-based compensation expense associated with grants of restricted stock units during the years ended June 30, 2023 and 2022, respectively. A summary of activity related to non-vested restricted stock units is presented below: Number of Weighted-Average Weighted-Average Nonvested restricted units outstanding at June 30, 2021 361,570 $ 2.51 1.3 Granted 304,421 2.78 — Vested ( 391,036 ) 2.62 — Forfeited ( 7,036 ) 2.35 — Nonvested restricted units outstanding at June 30, 2022 267,919 $ 2.66 1.2 Granted 534,628 1.14 1.5 Vested ( 353,649 ) 2.22 — Forfeited ( 8,750 ) 2.50 — Nonvested restricted units outstanding at June 30, 2023 440,148 $ 1.17 1.4 As of June 30, 2023, the Com pany had $ 362,281 of unrecognized stock compensation expense related to the restricted stock units, which will be recognized over the weighted average remaining service period of 1.43 year s. As of June 30, 2023, there were 1,646,522 shares available under the 2019 Plan for future grants and awards. Stock-based compensation expense recorded for stock options, restricted stock grants and restricted stock units for the years ended June 30, 2023 and 2022, total ed $ 1,932,415 and $ 2,267,186 , respectively.

Series B Convertible Preferred

Series B Convertible Preferred Stock	12 Months Ended
	Jun. 30, 2023
Temporary Equity Disclosure [Abstract]
Series B Convertible Preferred Stock	NOTE 14 - SERIES B CONVERTIBLE PREFERRED STOCK On February 18, 2022, the Company entered into a Securities Purchase Agreement, or the Purchase Agreement, with MFP, pursuant to which the Company sold and issued to MFP, in a private placement, 1,695 shares of its Series B Redeemable Convertible Non-Voting Preferred Stock, par value $ 0.001 per share, or the Series B Preferred Stock, and an accompanying warrant, or the Warrant, to purchase up to 559,350 shares of the Company’s common stock, or the Common Stock, par value $ 0.001 per share, at a combined unit price of $ 2,950 per share, or the Stated Value, for aggregate gross proceeds of approximately $ 5.0 million. The Warrant first becomes exercisable on the date that is six months after the date of issuance, at an exercise price of $ 5.00 per share (subject to adjustment in connection with any stock dividends and splits, distributions with respect to Common Stock and certain fundamental transactions as described in the Warrant) and will expire five years from the date it first becomes exercisable. The Series B Preferred Stock is initially convertible into shares of Common Stock at the rate of 1,000 shares of Common Stock per share of Series B Preferred Stock, at any time at the option of the holder of such shares, subject to the following limitations: (i) unless a holder was a stockholder of the Company as of February 18, 2022 (in which case such limitation shall not apply), the Company shall not effect any conversion of Series B Preferred Stock to the extent that, after giving effect to an attempted conversion, such holder, together with its affiliates, would beneficially own a number of shares of Common Stock in excess of 4.99 % of the total number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares, which limit may be decreased or increased (not to exceed 19.99 %) upon written notice to the Company, with any increase not becoming effective until at least 61 days after such notice; (ii) a holder may not acquire shares of Common Stock upon conversion of Series B Preferred Stock if such conversion would result in the total number of shares of Common Stock issued or issuable upon conversion or exercise of the securities issued pursuant to the Purchase Agreement to exceed 7,777,652 shares, or 19.99 % of the outstanding shares of Common Stock as of the date of the Purchase Agreement; and (iii) to the extent Nasdaq Listing Rule 5635(c) is applicable or deemed applicable to a holder, such holder may not acquire shares of Common Stock upon conversion of Series B Preferred Stock that would exceed the maximum number of all shares of Common Stock that could be issued by the Company to such holder without requiring stockholder approval pursuant to Nasdaq Listing Rule 5635(c). Upon receiving shareholder approval of a proposal to be submitted to the shareholders of the Company for the purpose of approving the transactions contemplated by the Purchase Agreement, pursuant to Nasdaq Listing Rules 5635(a), (c) and (d), the foregoing limitations in (ii) and (iii) above shall no longer have any force or effect. Pursuant to the Purchase Agreement, the Company agreed to use its reasonable best efforts to solicit the approval of its shareholders for the issuance of all shares of Common Stock otherwise issuable upon the conversion of the Series B Preferred Stock, or the Requisite Approval, at the next annual meeting of the Company’s shareholders, and at each annual meeting of shareholders thereafter, if necessary, until the Requisite Approval is obtained. A holder of Series B Preferred Stock is entitled to receive cumulative cash dividends of 5 % per annum, payable semi-annually in arrears on the last day of March and September of each calendar year. In lieu of paying such cash dividends, the Company may elect to add an amount to the Stated Value, provided that the dividend rate shall be 7 % per annum, calculated semi-annually in arrears on the last day of March and September of each calendar year. A holder of Series B Preferred Stock is also entitled to receive any dividend declared and paid to holders of the Common Stock as if such Series B Preferred Stock had been converted into Common Stock. In addition, a holder of Series B Preferred Stock is entitled to a liquidation preference equal to the greater of (i) the Stated Value, plus any cash dividends accrued but unpaid thereon, and (ii) the payment such holder would have received had the Series B Preferred Stock been converted into shares of Common Stock immediately prior to such liquidation event. Unless prohibited by Nevada law governing distributions to stockholders, the Series B Preferred Stock is redeemable, at any time after August 18, 2025, upon written request from the holders of a majority of the outstanding shares of Series B Preferred Stock, at a price equal to the Stated Value, plus any cash dividends accrued but unpaid thereon. The Series B Preferred Stock is non-voting except with respect to certain matters affecting the Series B Preferred Stock. In addition, the approval of a majority of the outstanding shares of Series B Preferred Stock is required if after Febr uary 18, 2022, the Company seeks to issue Common Stock, pursuant to the Sales Agreement, dated September 27, 2021, between the Company and B. Riley Securities, for cumulative gross proceeds in excess of $ 6.2 million. Since the holder has the option to redeem their shares of Series B Preferred Stock at any time after August 18, 2025, the stock is considered contingently redeemable and, accordingly, is classified as temporary equity on the consolidated balance sheets as of June 30, 2023. Over the initial 42 -month term the $ 4,638,521 rel ative fair value of the Series B Preferred Stock will be accreted to its redemption value of $ 5,000,250 . As of June 30, 2023, the Company has recognized $ 142,107 accretion of discount for warrants. Dividends will be accrued and recognized through retained earnings. As of June 30, 2023, $ 493,520 in dividends has been accrued. The following summarizes changes to our Series B Preferred Stock: Balance at June 30, 2021 $ — Issuance of preferred stock 4,638,521 Dividends accrued 127,541 Accretion of discount for warrants 38,757 Balance at June 30, 2022 $ 4,804,819 Dividends accrued 365,979 Accretion of discount for warrants 103,350 Balance at June 30, 2023 $ 5,274,148

Non-Cash Activities for Stateme

Non-Cash Activities for Statements of Cash Flows	12 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
NON-CASH ACTIVITIES FOR STATEMENTS OF CASH FLOWS	NOTE 15 - NON-CASH ACTIVITIES FOR STATEMENTS OF CASH FLOWS The below table represents supplemental information to the Company's consolidated statements of cash flows for non-cash activities during the years ended June 30, 2023 and 2022, respectively. Years Ended June 30, 2023 2022 Non-cash investing activities: ROU assets financed by lease liabilities $ 680,703 $ 369,574 Consideration received from Shell for equity interest in Vision Bioenergy: Settlement of long-term debt principal, interest and other related costs 6,860,838 — Note receivable 5,747,127 — Membership purchase option 695,000 — Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest ( 5,532,694 ) — Contribution of intangible assets to Trigall in exchange for equity investment and promissory note ( 1,750,000 ) — Non-cash financing activities: Warrants issued for financial commitment asset 1,894,901 — Dividends accrued for participating securities 365,979 127,541 Accretion of discount for Series B preferred stock warrants 103,350 38,757

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 - SUBSEQUENT EVENTS On September 25, 2023, the Company entered into a First Amendment to the Amended and Restated Loan and Security Agreement, or the Loan Amendment, with CIBC, which amended the Amended and Restated Loan and Security Agreement, dated March 22, 2023, or the CIBC Loan Agreement, by and among the Company, as borrower, and CIBC, as administrative agent and sole lead arranger. The Loan Amendment, among other things, (i) waived certain events of default under the CIBC Loan Agreement, (ii) eliminated the minimum EBITDA and fixed charge coverage ratio covenants for the period ending of June 30, 2024, (iii) increased the applicable interest rate margin on advances under the CIBC Loan Agreement by 0.5 % per annum (i.e. from 2.0 % to 2.5 % per annum), and (iv) added a fee of $ 75,000 payable by the Company to CIBC on the date of the Loan Amendment. Except as modified by the Loan Amendment, all terms and conditions of the CIBC Loan Agreement remain in full force and effect.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation a nd Principles of Consolidation The consolidated financial statements include the accounts of S&W Seed Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles, or GAAP, and include the assets, liabilities, revenue and expenses of all wholly-owned subsidiaries and majority-owned subsidiaries over which the Company's exercises control. Outside stockholders' interests in subsidiaries are shown in the consolidated financial statements as Noncontrolling interests. The Company own s 50.1 % of a venture based in South Africa named SeedVision Proprietary Limited, or SeedVision. SeedVision is a variable interest entity as defined in ASC 810-10, Consolidation, because no substantive equity contributions have been made to it, and SeedVision is being funded through advances, as needed, from its investors . The Company has concluded that it is the primary beneficiary of SeedVision because it has the power, through a tie-breaking vote on the board of directors, to direct the sales and marketing activities of SeedVision, which are considered to be the activities that have the greatest impact on the future economic performance of SeedVision. The Company owns 51.0 % of Sorghum Solutions South Africa, which is a variable interest entity as defined in ASC 810-10, Consolidation, because no substantive equity contributions have been made to it, and Sorghum Solutions South Africa is being funded through advances, as needed, from its investors . The Company has concluded that it is the primary beneficiary of Sorghum Solutions South Africa because it has the power, through a tie-breaking vote on the board of directors, to direct the sales and marketing activities of Sorghum Solutions South Africa, which are considered to be the activities that have the greatest impact on the future economic performance of Sorghum Solutions South Africa. Because the Company is their primary beneficiary, the financial results of SeedVision and Sorghum Solutions South Africa are included in these financial statements. The Company recorded a combined $ 289,517 of current assets (restricted) and $ 22,082 of current liabilities (nonrecourse) for these entities in our consolidated balance sheets as of June 30, 2023. The Company recorded a combined $ 459,909 of current assets (restricted) and $ 31,307 of current liabilities (nonrecourse) for these entities in our consolidated balance sheets as of June 30, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are adjusted to reflect actual experience when necessary. Significant estimates and assumptions affect many items in the financial statements. These include allowance for doubtful trade receivables, inventory valuation, the carrying value of the Company's equity investments, asset impairments, provisions for income taxes, grower accruals (an estimate of amounts payable to farmers who grow seed for the Company), contingencies and litigation. Significant estimates and assumptions are also used to establish the fair value and useful lives of depreciable tangible and certain intangible assets as well as valuing stock-based compensation. Actual results may differ from those estimates and assumptions, and such results may affect income, financial position or cash flows. The Company believes the estimates and assumptions underlying the accompanying consolidated financial statements are reasonable and supportable based on the information available at the time the financial statements were prepared. However, certain adverse geopolitical and macroeconomic events, such as the ongoing conflict between Ukraine and Russia and related sanctions, the armed conflict in Sudan, and uncertain market conditions, including higher inflation and supply chain disruptions, have, among other things, negatively impacted the global economy, created significant volatility and disruption of financial markets, and significantly increased economic and demand uncertainty. These factors make many of the estimates and assumptions reflected in these consolidated financial statements inherently less certain. Therefore, actual results may ultimately differ from those estimates to a greater degree than historically.
Certain Risks and Concentrations	Certain Risks and Concentrations The Company’s revenue is principally derived from the sale of seed, the market for which is highly competitive. The Company depends on a core group of signific ant customers. No single customer acco unted for more than 10 % of revenue for the years ended June 30, 2023 and 2022. No customer accou nted for more than 10 % of the Company’s accounts receivable at June 30, 2023 and June 30, 2022. The Company sells a substantial portion of its products to international customers. Sales to international markets represented 70 % a nd 73 % of revenue during the years ende d June 30, 2023 and 2022, respectively. The net book value of fixed assets located outside the United States was 31 % a nd 22 % of total fixed assets at June 30, 2023 and 2022, respectively. The following table shows revenue from external sources by destination country: Years Ended June 30, 2023 2022 United States $ 22,060,338 30 % $ 19,534,824 27 % Australia 17,414,681 24 % 21,673,461 30 % Saudi Arabia 9,781,138 13 % 9,528,777 13 % Mexico 5,502,421 8 % 1,915,370 3 % Libya 4,678,973 6 % 1,739,105 2 % Sudan 2,612,603 4 % 1,443,748 2 % Pakistan 2,494,981 3 % 3,309,800 5 % South Africa 1,620,601 2 % 1,898,467 3 % Argentina 1,162,369 2 % 1,541,402 2 % Algeria 912,040 1 % 430,000 1 % Other 5,281,146 7 % 8,339,344 12 % Total revenue $ 73,521,291 100 % $ 71,354,298 100 %
Liquidity and Going Concern	Liquidity and Going Concern The Company continues to monitor the ongoing military conflict between Russia and Ukraine and the armed conflict in Sudan on its business, including its results of operations and financial condition. The Company’s product revenue is predicated on its ability to timely fulfill customer orders, which depends in large part upon the consistent availability and operation of shipping and distribution networks operated by third parties. Farmers typically have a limited window during which they can plant seed and their buying decisions can be shaped by actual or perceived disruptions in the Company’s distribution and supply channels. If the Company’s customers delay or decrease their orders due to potential disruptions in its distribution and supply channels, or if the Company is unable to timely fulfill their orders, this would adversely affect the Company’s product revenue. During the year ended June 30, 2023, the Company experienced numerous logistical challenges due to limited availability of trucks for product deliveries, congestion at the ports, and overall increases in shipping and transportation costs. The Company expects these logistical challenges to persist well into fiscal 2024, which may, among other things, delay or reduce its ability to recognize revenue within a particular fiscal period and harm its results of operations. Excluding the gain recognized in relation to the Vision Bioenergy partnership, the Company is not profitable and has recorded negative op erating cash flows for the last several years. For the year ended June 30, 2023, the Company reported net loss, excluding the gain recognized from the Vision Bioenergy partnership, of $ 23.8 million and net cash used in operations of $ 19.0 million. As of June 30, 2023, the Company had cash on hand of $ 3.4 million. The Compa ny had $ 1.0 million of unused availability from its working capital facilities as of June 30, 2023 (refer to Note 8 for further discussion). In fiscal 2024, the Company is entitled to receive $ 6.0 million from Shell, subject to adjustment in certain circumstances detailed further in Note 7, and $ 1.0 million from Trigall in relation to the partnerships formed in fiscal 2023. The Company is obligated to make an additional $ 0.4 million in capital contributions to Trigall Australia through June 2025. The Company’s Amended and Restated Loan and Security Agreement, or the Amended CIBC Loan Agreement, with CIBC Bank USA, or CIBC, and its debt facilities with National Australia Bank, or NAB, listed under the NAB Finance Agreement, contain various operating and financial covenants (refer to Note 8). Adverse geopolitical and macroeconomic events and other factors affecting the Company’s results of operations have increased the risk of the Company’s inability to comply with these covenants, which could result in acceleration of its repayment obligations and foreclosure on its pledged assets. The Amended CIBC Loan Agreement as presently in effect requires the Company to meet minimum adjusted EBITDA levels on a quarterly basis, and the NAB Finance Agreement includes an undertaking that requires the Company to maintain a net related entity position of not more than USD $ 18.5 million and a minimum interest cover ratio at fiscal year-ends. As of June 30, 2023, the Company failed to meet the CIBC minimum adjusted EBITDA covenant as well as the NAB interest cover ratio covenant, but obtained waivers from both lenders with respect to such non-compliance. While the Company obtained waivers from CIBC and NAB for these failed covenants, there can be no assurance the Company will be successful in meeting its covenants or securing future waivers and/or amendments from its le nders. Currently, the Company does not expect to meet certain of these covenants in fiscal 2024. If the Company is unsuccessful in meeting its covenants or securing future waivers and/or amendments from its lenders and cannot obtain other financing options, it may need to reduce the scope of its operations, repay amounts owed t o its lenders and/or sell certain assets. Further, if the Company cannot renew or find other financing options when its two major debt facilities with CIBC and NAB expire on August 31, 2024 and September 30, 2024 , respectively, it m ay need to reduce the scope of its operations, repay amounts owed to its lenders and/or sell certain assets. These operating and liquidity factors raise substantial doubt regarding the Company’s ability to continue as a going concern. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified in order to conform to the current year presentation.
International Operations	International Operations The Company translates its foreign operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at the current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of accumulated other comprehensive income (loss). Gains or losses from foreign currency transactions are included in the consolidated statements of operations. For the year ended June 30, 2023, a $ 0.9 million foreign currency transaction gain was recognized within Cost of revenue and a $ 0.9 million foreign currency loss was recorded in Other expenses (income). For the year ended June 30, 2022, a $ 0.5 million foreign currency gain was recognized within Cost of revenue and a $ 0.8 million foreign currency loss was recorded to Other expenses (income).
Cost of Revenue	Cost of Revenue The Company records purchasing and receiving costs, inspection costs and warehousing costs in cost of revenue. When the Company is required to pay for outward freight and/or the costs incurred to deliver products to its customers, the costs are included in Cost of revenue.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement presentation purposes, the Company considers time deposits, certificates of deposit and all highly liquid investments with original maturities of three months or less to be cash and cash equivalents. At times, cash and cash equivalents balances exceed amounts insured by the Federal Deposit Insurance Corporation. Cash balances located outside of the United States may not be insured and totaled $ 191,766 and $ 811,551 on June 30, 2023 and 2022, respectively. Cash balances residing in the United States exceeding the Federal Deposit Insurance Corporation limit of $ 250,000 totaled $ 2,957,028 and $ 994,957 on June 30, 2023 and 2022, respectively.
Accounts Receivable	Accounts Receivable The Company provides an allowance for doubtful trade receivables equal to the estimated uncollectible amounts. That estimate is based on historical collection experience, current economic and market conditions and a review of the current status of each customer’s trade accounts receivable. The allowance for doubtful trade receivables was $ 209,757 and $ 233,927 at June 30, 2023 and June 30, 2022, respectively.
Inventories	Inventories Inventories consist of seed and packaging materials. Inventories are stated at the lower of cost or net realizable value, and an inventory reserve permanently reduces the cost basis of inventory. Inventories are valued as follows: Actual cost is used to value raw materials such as packaging materials, as well as goods in process. Costs for substantially all finished goods, which include the cost of carryover crops from the previous year, are valued at actual cost. Actual cost for finished goods includes plant conditioning and packaging costs, direct labor and raw materials and manufacturing overhead costs based on normal capacity. The Company records abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage) as current period charges and allocates fixed production overhead to the costs of finished goods based on the normal capacity of the production facilities. Inventory is periodically reviewed to determine if it is marketable, obsolete or impaired. Inventory that is determined to be obsolete or impaired is written off to expense at the time the impairment is identified. Inventory quality is a function of germination percentage. Our experience has shown that our alfalfa seed quality tends to be stable under proper storage conditions; therefore, we do not view inventory obsolescence for alfalfa seed as a material concern. Hybrid crops (sorghum and sunflower) seed quality may be affected by warehouse storage pests such as insects and rodents. The Company maintains a strict pest control program to mitigate risk and maximize hybrid seed quality. Components of inventory are: As of As of June 30, 2023 June 30, 2022 Raw materials and supplies $ 3,309,211 $ 2,645,764 Work in progress 6,409,554 6,677,980 Finished goods 35,379,503 45,192,150 Inventories, net $ 45,098,268 $ 54,515,894
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is depreciated using the straight-line method over the estimated useful life of the asset - periods of 5 to 35 years for buildings, 2 to 20 years for machinery and equipment, and 2 to 5 years for vehicles.
Intangible Assets	Intangible Assets Intangible assets acquired in business acquisitions are reported at their initial fair value less accumulated amortization. Intangible assets are amortized using the straight-line method over the estimated useful life of the asset. Periods of 10 to 30 years for technology/IP/germplasm, 5 to 20 years for customer relationships and trade names and 10 to 20 for other intangible assets. The weighted average estimated useful lives are 25 years for technology/IP/germplasm, 19 years for customer relationships, 16 years for trade names, and 18 years for other intangible assets.
Investments	Investments In fiscal 2023, the Company entered into two partnerships resulting in a 34 % ownership interest in Vision Bioenergy and a 20 % ownership interest in Trigall Australia. Following the initial recording of each investment, the Company assesses and records its share of equity earnings from each investment on a quarterly basis, resulting in the investment carrying value increasing or decreasing depending on whether a gain or loss is recorded. For Trigall Australia, the Company is also required to make capital contributions, which increases the carrying value of the investment.
Research and Development Costs	Research and Development Costs The Company is engaged in ongoing research and development, or R&D, of proprietary seed varieties. All R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results have been achieved. The costs associated with equipment or facilities acquired or constructed for R&D activities that have alternative future uses are capitalized and depreciated on a straight-line basis over the estimated useful life of the asset.
Employee Retention Credit	Employee Retention Credit In response to the COVID-19 pandemic, the Employee Retention Credit, or ERC, was established under the Coronavirus Aid, Relief, and Economic Security Act. The ERC is a refundable tax credit meant for businesses that continued to pay employees while shut down due to the COVID-19 pandemic or had significant declines in gross receipts from March 13, 2020 to December 31, 2021. Companies who meet the eligibility requirements can claim the ERC on an original or adjusted employment tax return for a period within those dates. In March 2023, the Company determined that it qualifies for $ 1.4 million in relief for the period from April 1, 2021 to September 30, 2021. Upon receipt of the relief, the Company will owe $ 0.2 million in tax advisory costs associated with the assessment of the tax credit. Further research is ongoing to determine if the Company qualifies for any other reporting periods. As there is no authoritative guidance under US GAAP for government assistance to for-profit business entities, the Company accounts for the ERC by analogy to International Accounting Standards 20, or IAS 20, Accounting for Government Grants and Disclosure of Government Assistance . In accordance with IAS 20, management determined it has reasonable assurance of receipt of the identified ERC amount and recorded the $ 1.4 million benefit under Government grant income in the consolidated statements of operations during the year ended June 30, 2023. A corresponding accrual of the tax credit receivable was recorded under Prepaid expenses and other current assets on the consolidated balance sheets as of June 30, 2023.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with the applicable accounting standards. These standards prescribe a minimum threshold a tax position is required to meet before being recognized in the consolidated financial statements. Deferred taxes are recognized for the estimated taxes ultimately payable or recoverable based on the enacted tax law. Changes in enacted tax rates are reflected in the tax provision as they occur. Deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities, as well as a consideration of net operating loss and credit carry forwards, using enacted tax rates in effect for the period in which the differences are expected to impact taxable income. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company’s effective tax rate for the years ended June 30, 2023 and 2022 has been affected by the valuation allowance on the Company’s deferred tax assets.
Net Income (Loss) Per Common Share Data	Net Income (Loss) Per Common Share Data Basic net income (loss) per common share, or EPS, is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted EPS is calculated by adjusting both the numerator (net income (loss)) and the denominator (weighted-average number of shares outstanding) for the dilutive effects of potentially dilutive securities, including options and restricted stock awards. The treasury stock method is used for stock options and restricted stock awards. Under this method, consideration that would be received upon exercise (as well as remaining compensation cost to be recognized for awards not yet vested) is assumed to be used to repurchase shares of stock in the market, with net number of shares assumed to be issued added to the denominator. The Company computes earnings per share using the two-class method. The two-class method requires an earnings allocation formula that determines earnings per share for common shareholders and participating security holders according to dividends declared and participating rights in undistributed earnings. The Series B Redeemable Convertible Non-Voting Preferred Stock, par value $ 0.001 per share, or the Series B Preferred Stock, and warrant are participating securities because holders of such shares have non-forfeitable dividend rights and participate in any undistributed earnings with common stock. Under the two-class method, total dividends provided to the holders of participating securities and undistributed earnings allocated to participating securities are subtracted from net income attributable to the Co mpany in determining net loss attributable to common shareholders. Additionally, any accretion to the redemption value for the Series B Preferred Stock is treated as a deemed dividend in the two-class EPS calculation. The calculation of basic and diluted EPS is shown in the table below: Years Ended June 30, 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 14,410,078 $ ( 36,395,350 ) Dividends accrued for participating securities ( 365,979 ) ( 127,541 ) Accretion of Series B Preferred Stock redemption value ( 103,350 ) ( 38,757 ) Numerator for net income (loss) per common share - basic and diluted $ 13,940,749 $ ( 36,561,648 ) Denominator: Denominator for basic EPS - weighted average shares 42,752,759 39,133,681 Less: weighted average shares - dilutive securities: Employee stock options 50,023 — Employee restricted stock options 132,769 — Denominator for diluted EPS - weighted average shares 42,935,551 39,133,681 Net income (loss) per common share - basic $ 0.33 $ ( 0.93 ) Net income (loss) per common share - diluted $ 0.32 $ ( 0.93 ) Anti-dilutive shares, which have been excluded from the computation of diluted income (loss) per share, included 4,851,886 employee stock options, 1,695,000 shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to purchase 2,633,400 shares of common stock related to the MFP Loan Agreement (as defined below), 559,350 warrants issued with the Company's Series B Convertible Preferred Stock, and 46,770 restricted stock units. The terms and conditions of these securities are more fully described in Note 12, Note 13, and Note 14 in these consolidated financial statements . For the period ended June 30, 2022, all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because net losses were recognized.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses or a forecasted inability to achieve break-even operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted future cash flows. Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. Refer to Note 5 for further impairment discussion.
Derivative Financial Instruments	Derivative Financial Instruments The Company’s subsidiary, S&W Australia, is exposed to foreign currency exchange rate fluctuations in the normal course of its business, which the Company at times manages through the use of foreign currency derivative financial instruments. The Company has entered into foreign currency forward contracts and foreign currency call options (refer to Note 10) and accounts for these instruments in accordance with ASC Topic 815, “Derivatives and Hedging,” which establishes accounting and reporting standards requiring that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. The Company’s foreign currency contracts and options are not designated as hedging instruments under ASC 815; accordingly, changes in the fair value are recorded in current period earnings. Premiums paid for foreign currency options with strike prices below the spot market price when acquired represent the time value of the option, as there is no intrinsic value. Such premiums are recorded as a current asset and amortized over the option term if deemed material. Currency options are measured at fair value if the market price at the reporting date exceeds the strike price. When the strike price exceeds the market price, no liability is recorded as the Company has no obligation to exercise the options.
Fair Values of Financial Instruments	Fair Value of Financial Instruments The Company discloses assets and liabilities that are recognized and measured at fair value, presented in a three-tier fair value hierarchy, as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The carrying value of cash and cash equivalents, accounts payable, short-term and all long-term borrowings, as reflected in the consolidated balance sheets, approximate fair value because of the short-term maturity of these instruments or interest rates commensurate with market rates. There have been no changes in operations and/or credit characteristics since the date of issuance that could impact the relationship between interest rate and market rates. S&W received a $ 6.0 million note receivable due from Shell in connection with the Vision Bioenergy partnership transaction (see Note 7). The note, which is due in February 2024, was initially recorded at its $ 5.7 million present value discounted at a rate of 4.4 %, which is ou r estimated discount rate for similar instruments. The receivable balance is being accreted to the full receivable amount on a straight-line basis over the remaining receivable term due to its short-term maturity. The receivable balance was $ 5.8 million at J une 30, 2023. Also in conjunction with the Vision Bioenergy partnership transaction, S&W received a one-time option, or Purchase Option, exercisable at any time on or before the fifth anniversary of the closing of the partnership transaction, to repurchase a 6 % membership interest from Shell. The option repurchase prices range between approximately $ 7.1 and $ 12.0 million, depending on the date on which such purchase is completed. The Purchase Option was valued at $ 0.7 million using a lattice option valuation model. The valuation model incorporated significant, unobservable inputs including a discounted cash flow model based on management projections of future Vision Bioenergy results and an estimate of the current per share value of Vision Bioenergy shares. In the model, the estimate of the current per share value was discounted to account for lack of control and marketability, which were considered to be part of the unit of account given the restrictions of the limited liability company agreement that governs the ownership rights of the members. Other unobservable inputs included the risk-free rates and the estimated future stock volatility based on the historical stock price volatilities of other market participants. A full fair value analysis will be performed at each fiscal year-end or when there is an indication that there may be an impairment to the valuation. Management will estimate and adjust the balance for interim periods. A fair value analysis was performed as of June 30, 2023, which resulted in no material adjustment to the fair value. Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 6/30/23 Valuation Technique Unobservable Input Range Purchase Option $ 695,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 % Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of June 30, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 849,033 $ — Note receivable due from Shell — 5,846,890 — Vision Bioenergy interest purchase option — — 695,000 Total $ — $ 6,695,923 $ 695,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ —
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements We have evaluated all issued and unadopted Accounting Standards Updates and believe the adoption of these standards will not have a material impact on our consolidated statements of operations, comprehensive income, balance sheets, or cash flows.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Revenues from External Customers by Country	The following table shows revenue from external sources by destination country: Years Ended June 30, 2023 2022 United States $ 22,060,338 30 % $ 19,534,824 27 % Australia 17,414,681 24 % 21,673,461 30 % Saudi Arabia 9,781,138 13 % 9,528,777 13 % Mexico 5,502,421 8 % 1,915,370 3 % Libya 4,678,973 6 % 1,739,105 2 % Sudan 2,612,603 4 % 1,443,748 2 % Pakistan 2,494,981 3 % 3,309,800 5 % South Africa 1,620,601 2 % 1,898,467 3 % Argentina 1,162,369 2 % 1,541,402 2 % Algeria 912,040 1 % 430,000 1 % Other 5,281,146 7 % 8,339,344 12 % Total revenue $ 73,521,291 100 % $ 71,354,298 100 %
Components of Inventory	Components of inventory are: As of As of June 30, 2023 June 30, 2022 Raw materials and supplies $ 3,309,211 $ 2,645,764 Work in progress 6,409,554 6,677,980 Finished goods 35,379,503 45,192,150 Inventories, net $ 45,098,268 $ 54,515,894
Schedule of Calculation of Basic and Diluted EPS	The calculation of basic and diluted EPS is shown in the table below: Years Ended June 30, 2023 2022 Numerator: Net income (loss) attributable to S&W Seed Company $ 14,410,078 $ ( 36,395,350 ) Dividends accrued for participating securities ( 365,979 ) ( 127,541 ) Accretion of Series B Preferred Stock redemption value ( 103,350 ) ( 38,757 ) Numerator for net income (loss) per common share - basic and diluted $ 13,940,749 $ ( 36,561,648 ) Denominator: Denominator for basic EPS - weighted average shares 42,752,759 39,133,681 Less: weighted average shares - dilutive securities: Employee stock options 50,023 — Employee restricted stock options 132,769 — Denominator for diluted EPS - weighted average shares 42,935,551 39,133,681 Net income (loss) per common share - basic $ 0.33 $ ( 0.93 ) Net income (loss) per common share - diluted $ 0.32 $ ( 0.93 ) Anti-dilutive shares, which have been excluded from the computation of diluted income (loss) per share, included 4,851,886 employee stock options, 1,695,000 shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to purchase 2,633,400 shares of common stock related to the MFP Loan Agreement (as defined below), 559,350 warrants issued with the Company's Series B Convertible Preferred Stock, and 46,770 restricted stock units. The terms and conditions of these securities are more fully described in Note 12, Note 13, and Note 14 in these consolidated financial statements . For the period ended June 30, 2022, all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because net losses were recognized.
Schedule of Quantitative Information About Level 3 Fair Value Measurement	Quantitative information about Level 3 fair value measurement is as follows: Fair Value at 6/30/23 Valuation Technique Unobservable Input Range Purchase Option $ 695,000 Option Model Risk-free rate 3.8 % - 4.9 % Stock price volatility 60 % - 65 % Lack of control premium 13 % Lack of marketability premium 30 %
Schedule of Assets and Liabilities Recognized and Measured at Fair Value on Recurring Basis	Assets and liabilities that are recognized and measured at fair value on a recurring basis are categorized as follows: Fair Value Measurements as of June 30, 2023 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 849,033 $ — Note receivable due from Shell — 5,846,890 — Vision Bioenergy interest purchase option — — 695,000 Total $ — $ 6,695,923 $ 695,000 Fair Value Measurements as of June 30, 2022 Using: Level 1 Level 2 Level 3 Foreign exchange contract liability $ — $ 996,106 $ — Total $ — $ 996,106 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2023
Lessee Disclosure [Abstract]
Summary of Components of Lease Assets and Liabilities	The components of lease assets and liabilities are as follows: As of June 30, Leases Balance Sheet Classification: 2023 2022 Assets: Right of use assets - finance leases $ 1,759,094 $ 2,071,609 Accumulated amortization - finance leases ( 1,088,294 ) ( 1,131,842 ) Right of use assets - finance leases, net Other assets 670,800 939,767 Right of use assets - operating leases Right of use assets - operating leases 2,983,303 4,094,253 Total lease assets $ 3,654,103 $ 5,034,020 Liabilities: Current lease liabilities - finance leases Current portion of long-term debt, net $ 383,403 $ 804,309 Current lease liabilities - operating leases Accrued expenses and other current liabilities 1,335,568 1,341,198 Long-term portion of lease liabilities - Long-term debt, net, less current portion 304,761 500,723 Long-term portion of lease liabilities - Other non-current liabilities 1,949,604 3,042,311 Total lease liabilities $ 3,973,336 $ 5,688,541
Summary of Components of Lease Cost	The components of lease cost are as follows: Years Ended June 30, Lease cost: Income Statement Classification: 2023 2022 Operating lease cost Cost of revenue $ 708,802 $ 692,210 Operating lease cost Selling, general and administrative expenses 195,842 307,368 Operating lease cost Research and development expenses 437,282 375,905 Finance lease cost Depreciation and amortization 505,082 625,625 Finance lease cost Interest expense, net 40,817 89,577 Total lease costs $ 1,887,825 $ 2,090,685
Summary of Maturities of Lease Liabilities	Maturities of lease liabilities as of June 30, 2023 are as follows: Fiscal Year Operating Leases Finance Leases 2024 $ 1,454,919 $ 420,368 2025 953,677 212,098 2026 621,696 114,141 2027 397,469 — 2028 99,432 — Total lease payments 3,527,193 746,607 Less: Interest ( 242,021 ) ( 58,443 ) Present value of lease liabilities $ 3,285,172 $ 688,164
Summary of Weighted Average Assumptions on Lease Term and Discount Rate and Supplemental Cash Flow Information Related to Leases	The following are the weighted average assumptions used for lease term and discount rate and supplemental cash flow information related to leases as of June 30, 2023: Operating lease remaining lease term 3.1 years Operating lease discount rate 4.14 % Finance lease remaining lease term 0.8 years Finance lease discount rate 6.69 % Cash paid for operating leases $ 1,449,629 Cash paid for finance leases $ 624,863

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Jun. 30, 2023
Revenues [Abstract]
Schedule of disaggregation of revenues	The Company disaggregates revenue by type of contract and by destination country. The following table shows revenue from external sources by type of contract: Years Ended June 30, 2023 2022 Seed sales $ 72,808,112 $ 69,425,407 Services 713,179 1,928,891 Total revenue $ 73,521,291 $ 71,354,298

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Activity of Goodwill	The following table summarizes the activity of goodwill for the year ended June 30, 2022: Balance at Additions Impairment Currency Translation Adjustment Balance at Goodwill $ 1,651,634 $ — $ ( 1,548,324 ) $ ( 103,310 ) $ — Intangible Assets
Schedule of Intangible Assets	Intangible assets consist of the following: Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Intellectual property $ 23,035,925 $ — $ ( 1,385,391 ) $ — $ 21,650,534 Trade name 1,084,791 - ( 196,627 ) ( 7,231 ) 880,933 Customer relationships 5,499,815 — ( 353,000 ) ( 178,140 ) 4,968,675 GI customer list 42,983 — ( 7,164 ) — 35,819 Supply agreement 775,241 — ( 75,633 ) — 699,608 Grower relationships 1,331,581 — ( 105,406 ) — 1,226,175 License agreement 1,986,598 ( 1,885,907 ) ( 75,610 ) ( 25,081 ) — Internal use software 338,893 — ( 67,778 ) — 271,115 $ 34,095,827 $ ( 1,885,907 ) $ ( 2,266,609 ) $ ( 210,452 ) $ 29,732,859 Balance at Other Additions and Disposals Amortization Currency Translation Adjustment Balance at Intellectual property $ 24,427,857 $ — $ ( 1,391,932 ) $ — $ 23,035,925 Trade name 1,310,489 - ( 203,009 ) ( 22,689 ) 1,084,791 Customer relationships 6,302,591 — ( 373,393 ) ( 429,383 ) 5,499,815 Non-compete 5,058 — ( 5,058 ) — — GI customer list 50,146 — ( 7,163 ) — 42,983 Supply agreement 850,874 — ( 75,633 ) — 775,241 Grower relationships 1,436,988 — ( 105,407 ) — 1,331,581 License agreement 2,340,269 — ( 172,004 ) ( 181,667 ) 1,986,598 Internal use software 406,670 — ( 67,777 ) — 338,893 $ 37,130,942 $ — $ ( 2,401,376 ) $ ( 633,739 ) $ 34,095,827
Intangible Assets (Future Amortization)	Estimated aggregate remaining amortization is as follows: 2024 2025 2026 2027 2028 Thereafter Amortization expense $ 2,179,262 $ 2,139,453 $ 2,025,950 $ 1,921,799 $ 1,864,508 $ 19,601,887

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	Components of property, plant and equipment were as follows: As of As of June 30, 2023 June 30, 2022 Land and improvements $ 939,089 $ 2,265,087 Buildings and improvements 3,356,755 8,119,960 Machinery and equipment 12,667,858 14,972,462 Vehicles 605,891 1,085,342 Leasehold improvements 552,810 552,810 Construction in progress 177,538 110,107 Total property, plant and equipment 18,299,941 27,105,768 Less: accumulated depreciation ( 8,217,773 ) ( 10,234,099 ) Property, plant and equipment, net $ 10,082,168 $ 16,871,669

Investments (Tables)

Investments (Tables)	12 Months Ended
	Jun. 30, 2023
Schedule of Equity Method Investments [Line Items]
Schedule of Gain on Equity Method Investments	This consideration is summarized below: Amount Received (Contributed) Equity investment $ 23,396,832 Cash 7,000,000 Debt retirement 6,860,838 Notes receivable, net 5,747,126 Fair value of 6 % member purchase option 695,000 Fixed assets and inventory transfer ( 5,532,694 ) Gain on equity method investments $ 38,167,102
Summary of Equity Method Investments	The following summarizes the carrying amount of the Company's equity method investments reflected in the consolidated balance sheets: June 30, 2023 June 30, 2022 Carrying Amount Economic Interest Carrying Amount Economic Interest Vision Bioenergy $ 22,307,486 34 % $ — 0 % Trigall Australia 752,219 20 % — 0 % Bioceres — 0 % 367,970 1 % Total equity method investments $ 23,059,705 $ 367,970
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Summary of Equity Method Investments	The summarized unaudited balance sheet presented below reflects the financial infor mation of Vision Bioenergy as of June 30, 2023: As of June 30, 2023 (Unaudited) Cash $ 8,973,896 Other current assets 747,090 Fixed assets 15,051,799 Intangible assets 18,575,108 Goodwill 11,870,376 Other assets 255,899 TOTAL ASSETS $ 55,474,168 Current liabilities 1,381,493 Long-term liabilities 176,203 Equity 53,916,472 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 55,474,168 The summarized unaudited income statement presented below reflects the financial information of Vision Bioenergy for the period from February 6, 2023 (inception) through June 30, 2023: Year Ended June 30, 2023 (Unaudited) Revenue $ 168,977 Gross profit (loss) ( 726,502 ) Loss from operations ( 3,358,348 ) Net loss ( 3,203,958 )

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Schedule of Total Debt Outstanding	Total debt outstanding is presented on the consolidated balance sheets as follows: June 30, 2023 June 30, 2022 Current portion of working capital lines of credit CIBC $ 19,335,427 $ 12,804,611 National Australia Bank Limited 25,938,839 338,314 Debt issuance costs ( 373,487 ) ( 464,028 ) Total current portion of working capital lines of credit, net 44,900,779 12,678,897 Long-term portion of working capital lines of credit, less current portion National Australia Bank Limited — 21,703,286 Total working capital lines of credit, net $ 44,900,779 $ 34,382,183 Current portion of long-term debt Finance leases $ 383,403 $ 804,309 Term Loan - National Australia Bank Limited 2,318,050 344,400 Machinery & equipment loans - National Australia Bank Limited 1,141,349 246,547 Machinery & equipment loans - Hyster 11,902 11,834 Vehicle loans - Ford Credit 51,278 40,341 Secured real estate note - Rooster — 6,905,995 Debt issuance costs ( 97,221 ) ( 36,643 ) Total current portion, net 3,808,761 8,316,783 Long-term debt, less current portion Finance leases 304,761 500,723 Term loan - National Australia Bank Limited — 2,410,800 Machinery & equipment loans - National Australia Bank Limited — 963,733 Machinery & equipment loans - Hyster 15,715 28,722 Vehicle loans - Ford Credit 70,103 88,583 Secured real estate note - AgAmerica 4,300,000 — Debt issuance costs ( 191,245 ) ( 21 ) Total long-term portion, net 4,499,334 3,992,540 Total debt, net $ 8,308,095 $ 12,309,323
Schedule of Annual Maturities of Long-Term Debt Excluding Finance Lease Liabilities	The annual maturities of long-term debt, excluding finance lease liabilities, are as follows: Fiscal Year Amount 2024 $ 3,522,579 2025 75,904 2026 4,309,914 Total $ 7,908,397

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Income (Loss) Before Income Taxes	Income (loss) before income taxes consists of the following: Years Ended June 30, 2023 2022 United States $ 20,631,632 $ ( 37,346,576 ) Foreign ( 5,707,581 ) 1,437,493 Income (loss) before income taxes $ 14,924,051 $ ( 35,909,083 )
Components of Provision for Income Taxes	Significant components of the provision for income taxes from continuing operations are as follows: Years Ended June 30, 2023 2022 Current: State 12,431 301 Foreign 42,480 266,129 Total current provision 54,911 266,430 Deferred: Federal — ( 1 ) Foreign ( 818,550 ) 146,994 Total deferred provision ( 818,550 ) 146,993 Provision for (benefit from) income taxes $ ( 763,639 ) $ 413,423
Reconciliation of Income Tax Provision and Expected Income Tax Computed Using U.S. Federal Income Tax Rate	The differences between the total calculated income tax provision and the expected income tax computed using the U.S. federal income tax rate are as follows: Years Ended June 30, 2023 2022 Tax benefit at statutory tax rate $ 3,134,080 $ ( 7,540,908 ) State benefit, net of federal benefit 388,572 ( 493,262 ) Estimated GILTI Inclusion 267,352 — Federal and state research credits - current year 67,144 ( 390,235 ) Other permanent differences ( 187,808 ) 184,725 Foreign rate differential ( 521,188 ) 420,829 Goodwill impairment — 549,577 Valuation allowance ( 5,371,275 ) 7,573,300 Transfer Pricing Adjustments 1,380,810 — Stock Compensation 266,127 — Equity method investments ( 277,952 ) — Other 90,499 109,397 Provision for (benefit from) income taxes $ ( 763,639 ) $ 413,423
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred tax assets and liabilities are as follows: 2023 2022 Deferred tax assets: Net operating loss carry forwards $ 21,170,710 $ 22,815,372 Tax credit carryforwards 2,184,461 1,388,106 Allowance for bad debts 1,184,158 1,216,187 Goodwill 1,688,905 1,597,873 Lease liability 880,955 1,187,090 Interest expense carryforwards 1,446,422 1,144,535 Other, net 2,588,490 1,756,460 Total deferred tax assets 31,144,101 31,105,623 Valuation allowance for deferred tax assets ( 22,061,576 ) ( 27,437,845 ) Deferred tax assets, net of valuation allowance 9,082,525 3,667,778 Deferred tax liabilities: ROU lease asset ( 903,508 ) ( 1,226,879 ) Equity method investments ( 4,620,682 ) — Intangible assets ( 1,910,044 ) ( 1,381,955 ) Fixed assets ( 1,160,228 ) ( 1,382,821 ) Total deferred tax liabilities ( 8,594,462 ) ( 3,991,655 ) Net deferred tax asset (liability) $ 488,063 $ ( 323,877 )
Summarized Activity Related to Unrecognized Tax Benefits	The following table summarized the activity related to our unrecognized tax benefits: Years Ended June 30, 2023 2022 Beginning Balance $ 77,350 $ 79,341 Other ( 431 ) ( 1,991 ) Ending Balance $ 76,919 $ 77,350

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2023
Schedule of Weighted Average Assumptions Used in Black-Scholes-Merton Model	Weighted average assumptions used in the Black-Scholes-Merton model are set forth below: June 30, 2023 2022 Risk free rate 2.9 % - 4.4 % 0.8 % - 2.8 % Dividend yield — — Volatility 64.7 % - 66.1 % 61.7 % - 64.7 % Forfeiture rate 9.1 % 3.2 %
Summary of Stock Option Activity	A summary of stock option activity for the years ended June 30, 2023 and 2022 is presented below: Number of Weighted - Weighted- Aggregate Outstanding at June 30, 2021 3,776,568 $ 2.65 8.0 $ 3,962,766 Granted 994,725 2.63 Exercised ( 38,774 ) 2.33 Canceled/forfeited/expired ( 95,419 ) 2.82 Outstanding at June 30, 2022 4,637,100 $ 2.64 6.6 $ — Granted 1,389,675 1.25 Exercised ( 2,100 ) 0.95 Canceled/forfeited/expired ( 947,707 ) 2.84 Outstanding at June 30, 2023 5,076,968 $ 2.23 7.1 $ 292,079 Options vested and exercisable at June 30, 2023 3,685,678 $ 2.47 6.3 $ 59,669 Options vested and expected to vest as of June 30, 2023 5,066,581 $ 2.23 7.1 $ 289,227
Summary of Activity Related to Non-Vested Restricted Stock Units	A summary of activity related to non-vested restricted stock units is presented below: Number of Weighted-Average Weighted-Average Nonvested restricted units outstanding at June 30, 2021 361,570 $ 2.51 1.3 Granted 304,421 2.78 — Vested ( 391,036 ) 2.62 — Forfeited ( 7,036 ) 2.35 — Nonvested restricted units outstanding at June 30, 2022 267,919 $ 2.66 1.2 Granted 534,628 1.14 1.5 Vested ( 353,649 ) 2.22 — Forfeited ( 8,750 ) 2.50 — Nonvested restricted units outstanding at June 30, 2023 440,148 $ 1.17 1.4

Series B Convertible Preferre_2

Series B Convertible Preferred Stock (Tables)	12 Months Ended
	Jun. 30, 2023
Temporary Equity Disclosure [Abstract]
Summary of Changes to Series B Preferred Stock	The following summarizes changes to our Series B Preferred Stock: Balance at June 30, 2021 $ — Issuance of preferred stock 4,638,521 Dividends accrued 127,541 Accretion of discount for warrants 38,757 Balance at June 30, 2022 $ 4,804,819 Dividends accrued 365,979 Accretion of discount for warrants 103,350 Balance at June 30, 2023 $ 5,274,148

Non-Cash Activities for State_2

Non-Cash Activities for Statements of Cash Flows (Tables)	12 Months Ended
	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Consolidated Statements of Cash Flows for Non-Cash Activities	Years Ended June 30, 2023 2022 Non-cash investing activities: ROU assets financed by lease liabilities $ 680,703 $ 369,574 Consideration received from Shell for equity interest in Vision Bioenergy: Settlement of long-term debt principal, interest and other related costs 6,860,838 — Note receivable 5,747,127 — Membership purchase option 695,000 — Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest ( 5,532,694 ) — Contribution of intangible assets to Trigall in exchange for equity investment and promissory note ( 1,750,000 ) — Non-cash financing activities: Warrants issued for financial commitment asset 1,894,901 — Dividends accrued for participating securities 365,979 127,541 Accretion of discount for Series B preferred stock warrants 103,350 38,757

Background and Organization - A

Background and Organization - Additional Information (Details)	Jun. 30, 2023	Feb. 06, 2023	Dec. 23, 2022	Jun. 30, 2022
Vision Bioenergy
Background And Organizations [Line Items]
Ownership interest	34%	34%		0%
Trigall Australia Pty Ltd
Background And Organizations [Line Items]
Ownership interest	20%		20%	0%
Shell | Vision Bioenergy
Background And Organizations [Line Items]
Ownership interest		66%
S&W Australia | Trigall Australia Pty Ltd
Background And Organizations [Line Items]
Ownership interest			80%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)					1 Months Ended		5 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares	Feb. 06, 2023 USD ($)	Dec. 23, 2022 USD ($)	Dec. 26, 2019	Mar. 31, 2023 USD ($)	Feb. 29, 2020 USD ($)	Jun. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($) Customer $ / shares shares	Jun. 30, 2022 USD ($) Customer	Sep. 22, 2022 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Current assets (restricted)	$ 289,517						$ 289,517	$ 289,517	$ 459,909
Current liabilities (nonrecourse)	$ 22,082						$ 22,082	$ 22,082	$ 31,307
Net book value of fixed assets located outside the United States, percent of total	31%						31%	31%	22%
Cash balances	$ 2,957,028						$ 2,957,028	$ 2,957,028	$ 994,957
Net loss								(14,435,360)	36,322,506
Net loss excluding gain from Vision Bioenergy Partnership								23,800,000
Net cash used in operations								18,978,150	18,373,139
Cash on hand	3,400,000						3,400,000	3,400,000
Line of credit facility, remaining borrowing capacity	1,000,000						1,000,000	1,000,000
Borrowings of long-term debt								4,208,460	868,372
Foreign currency gain								(859,696)	(777,913)
Employee retention credit relief					$ 1,400,000
Owe tax advisory costs upon relief					$ 200,000
Government grant income								1,444,044	0
Equity investment	$ 23,059,705						$ 23,059,705	$ 23,059,705	367,970
Par value per share | $ / shares	$ 0.001						$ 0.001	$ 0.001
Federal deposit cash	$ 250,000						$ 250,000	$ 250,000
Allowance for doubtful trade receivables	209,757						209,757	$ 209,757	233,927
Goodwill acquire transaction									0
Shell
Summary Of Significant Accounting Policies [Line Items]
Receivables discount rate		4.40%
Membership interest repurchase percent		6%
Fair market value of purchase option		$ 700,000
Employee Stock Options
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share | shares								4,851,886
Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share | shares								1,695,000
Shares of Common Stock Related to MFP Loan Agreement
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share | shares								2,633,400
Warrants Issued with Series B Convertible Preferred Stock
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share | shares								559,350
Restricted Stock Units (RSUs)
Summary Of Significant Accounting Policies [Line Items]
Anti-dilutive shares, excluded from computation of diluted income (loss) per share | shares								46,770
Cost of Revenue
Summary Of Significant Accounting Policies [Line Items]
Foreign currency gain								$ 900,000	500,000
Other Expense (Income)
Summary Of Significant Accounting Policies [Line Items]
Foreign currency gain								900,000	800,000
ATM Agreement | B. Riley Securities, Inc
Summary Of Significant Accounting Policies [Line Items]
Value of remaining common stock available to sell under agreement	6,200,000						6,200,000	$ 6,200,000
Pasture Genetics Acquisition
Summary Of Significant Accounting Policies [Line Items]
Goodwill acquire transaction						$ 1,452,436
Technology/IP
Summary Of Significant Accounting Policies [Line Items]
Useful life								25 years
Customer Relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life								19 years
Trade Name
Summary Of Significant Accounting Policies [Line Items]
Useful life								16 years
Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life								18 years
CIBC
Summary Of Significant Accounting Policies [Line Items]
Line of credit facility, remaining borrowing capacity	800,000						800,000	$ 800,000
Debt instrument, maturity date			Mar. 23, 2023	Dec. 23, 2022				Aug. 31, 2024
CIBC | Line of Credit
Summary Of Significant Accounting Policies [Line Items]
Net due from related entities covenant maximum	18,500,000						18,500,000	$ 18,500,000
Minimum potential liquidity raised to meet covenant compliance										$ 1,000,000
NAB
Summary Of Significant Accounting Policies [Line Items]
Debt instrument, maturity date								Sep. 30, 2024
Non-US
Summary Of Significant Accounting Policies [Line Items]
Cash balances	$ 191,766						191,766	$ 191,766	$ 811,551
UNITED STATES
Summary Of Significant Accounting Policies [Line Items]
Disclosure on Geographic Areas, Fixed Assets									The net book value of fixed assets located outside the United States was 31% and 22% of total fixed assets at June 30, 2023 and 2022, respectively.
Maximum | Shell
Summary Of Significant Accounting Policies [Line Items]
Additional proceeds to be received from sale of businesses in one year							$ 6,000,000
Membership interest repurchase price		12,000,000
Maximum | Technology/IP
Summary Of Significant Accounting Policies [Line Items]
Useful life								30 years
Maximum | Customer Relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life								20 years
Maximum | Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life								20 years
Maximum | Building
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	35 years						35 years	35 years
Maximum | Machinery and Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	20 years						20 years	20 years
Maximum | Vehicles
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	5 years						5 years	5 years
Minimum | Shell
Summary Of Significant Accounting Policies [Line Items]
Membership interest repurchase price		7,100,000
Minimum | Technology/IP
Summary Of Significant Accounting Policies [Line Items]
Useful life								10 years
Minimum | Customer Relationships
Summary Of Significant Accounting Policies [Line Items]
Useful life								5 years
Minimum | Other Intangibles
Summary Of Significant Accounting Policies [Line Items]
Useful life								10 years
Minimum | Building
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	5 years						5 years	5 years
Minimum | Machinery and Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	2 years						2 years	2 years
Minimum | Vehicles
Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives	2 years						2 years	2 years
Customer Concentration Risk | Revenue | Significant Customer
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer								0	0
Concentration risk, percentage								10%	10%
Credit Concentration Risk | Accounts Receivable | Significant Customer
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer								0	0
Concentration risk, percentage								10%	10%
Geographic Concentration Risk | Revenue | Non-US
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage								70%	73%
Vision Bioenergy
Summary Of Significant Accounting Policies [Line Items]
Equity investment	$ 22,307,486	$ 23,400,000					$ 22,307,486	$ 22,307,486
Ownership interest	34%	34%					34%	34%	0%
Vision Bioenergy | Shell
Summary Of Significant Accounting Policies [Line Items]
Notes receivable, net	$ 5,800,000	$ 5,700,000					$ 5,747,126
Equity investment		$ 23,396,832
Membership interest repurchase percent		6%
Fair market value of purchase option		$ 695,000						$ 695,000
Ownership interest		66%
Vision Bioenergy | Maximum | Shell
Summary Of Significant Accounting Policies [Line Items]
Additional proceeds to be received from sale of businesses in one year		$ 6,000,000
Trigall Australia
Summary Of Significant Accounting Policies [Line Items]
Additional proceeds to be received from sale of businesses in one year			$ 1,000,000
Additional capital contributions to be made in next two years								400,000
Equity investment	$ 752,219		$ 800,000				$ 752,219	$ 752,219
Ownership interest	20%		20%				20%	20%	0%
SeedVision | Variable Interest Entity
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage in variable interest entity								50.10%
Sorghum Solutions | Variable Interest Entity
Summary Of Significant Accounting Policies [Line Items]
Ownership percentage in variable interest entity								51%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Revenues from External Customers by Country (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 73,521,291	$ 71,354,298
Revenue from external customers by country, percentage	100%	100%
United States
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 22,060,338	$ 19,534,824
Revenue from external customers by country, percentage	30%	27%
Australia
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 17,414,681	$ 21,673,461
Revenue from external customers by country, percentage	24%	30%
Saudi Arabia
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 9,781,138	$ 9,528,777
Revenue from external customers by country, percentage	13%	13%
Mexico
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 5,502,421	$ 1,915,370
Revenue from external customers by country, percentage	8%	3%
Libya
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 4,678,973	$ 1,739,105
Revenue from external customers by country, percentage	6%	2%
Sudan
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 2,612,603	$ 1,443,748
Revenue from external customers by country, percentage	4%	2%
Pakistan
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 2,494,981	$ 3,309,800
Revenue from external customers by country, percentage	3%	5%
South Africa
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 1,620,601	$ 1,898,467
Revenue from external customers by country, percentage	2%	3%
Argentina
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 1,162,369	$ 1,541,402
Revenue from external customers by country, percentage	2%	2%
Algeria
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 912,040	$ 430,000
Revenue from external customers by country, percentage	1%	1%
Other
Disaggregation Of Revenue [Line Items]
Revenues from external customers	$ 5,281,146	$ 8,339,344
Revenue from external customers by country, percentage	7%	12%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Components of Inventory (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 3,309,211	$ 2,645,764
Work in progress	6,409,554	6,677,980
Finished goods	35,379,503	45,192,150
Inventories, net	$ 45,098,268	$ 54,515,894

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Calculation of Basic and Diluted EPS (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss attributable to S&W Seed Company	$ 14,410,078	$ (36,395,350)
Dividends accrued for participating securities	(365,979)	(127,541)
Accretion of Series B Preferred Stock redemption value	(103,350)	(38,757)
Numerator for net income (loss) per common share - basic	13,940,749	(36,561,648)
Numerator for net income (loss) per common share - diluted	$ 13,940,749	$ (36,561,648)
Denominator:
Denominator for basic EPS - weighted average shares	42,752,759	39,133,681
Weighted average number of common shares outstanding:
Employee stock options	50,023
Employee restricted stock units	132,769
Denominator for diluted EPS - adjusted weighted average shares and assumed conversions	42,935,551	39,133,681
Net income (loss) per common share - basic	$ 0.33	$ (0.93)
Net income (loss) per common share - diluted	$ 0.32	$ (0.93)

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Quantitative Information About Level 3 Fair Value Measurement (Details)	Jun. 30, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Valuation Technique [Extensible Enumeration]	us-gaap:ValuationTechniqueOptionPricingModelMember
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Purchase option	$ 695,000
Lack of control premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	13
Lack of marketability premium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	30
Maximum | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	4.9
Maximum | Stock price volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	65
Minimum | Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	3.8
Minimum | Stock price volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset, Measurement Input	60

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Recognized and Measured at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	$ 0	$ 0
Note receivable due from Shell	0
Vision Bioenergy interest purchase option	0
Total	0	0
Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	849,033	996,106
Note receivable due from Shell	5,846,890
Vision Bioenergy interest purchase option	0
Total	6,695,923	996,106
Level 3
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Foreign exchange contract liability	0	0
Note receivable due from Shell	0
Vision Bioenergy interest purchase option	695,000
Total	$ 695,000	$ 0

Leases - Additional Information

Leases - Additional Information (Details)	12 Months Ended
	Jun. 30, 2023
Operating And Finance Lease [Line Items]
Lessee, operating lease, option to extend, description	If the lease includes one or more options to extend the term of the lease, the renewal option is considered in the lease term if it is reasonably certain the Company will exercise the option(s). Operating lease expense is recognized on a straight-line basis over the term of the lease.
Lessee, operating lease, option to extend	true
Maximum
Operating And Finance Lease [Line Items]
Lease agreements term	1 year

Leases - Summary of Components

Leases - Summary of Components of Lease Assets and Liabilities (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Lessee Disclosure [Abstract]
Right of use assets - finance leases	$ 1,759,094	$ 2,071,609
Accumulated amortization - finance leases	(1,088,294)	(1,131,842)
Right of use assets - finance leases, net	$ 670,800	$ 939,767
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Right of use assets - operating leases	$ 2,983,303	$ 4,094,253
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Right of use assets - operating leases	Right of use assets - operating leases
Total lease assets	$ 3,654,103	$ 5,034,020
Current lease liabilities - finance leases	$ 383,403	$ 804,309
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Current portion of long-term debt, net	Current portion of long-term debt, net
Current lease liabilities - operating leases	$ 1,335,568	$ 1,341,198
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued expenses and other current liabilities	Accrued expenses and other current liabilities
Long-term portion of lease liabilities - finance leases	$ 304,761	$ 500,723
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term debt, net, less current portion	Long-term debt, net, less current portion
Long-term portion of lease liabilities - operating leases	$ 1,949,604	$ 3,042,311
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities	Other non-current liabilities
Total lease liabilities	$ 3,973,336	$ 5,688,541

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Lessee Lease Description [Line Items]
Total lease costs	$ 1,887,825	$ 2,090,685
Cost of Revenue
Lessee Lease Description [Line Items]
Operating lease cost	708,802	692,210
Selling, General and Administrative Expenses
Lessee Lease Description [Line Items]
Operating lease cost	195,842	307,368
Research and Development Expenses
Lessee Lease Description [Line Items]
Operating lease cost	437,282	375,905
Depreciation and Amortization
Lessee Lease Description [Line Items]
Finance lease cost	505,082	625,625
Interest expense, net
Lessee Lease Description [Line Items]
Finance lease cost	$ 40,817	$ 89,577

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Details)	Jun. 30, 2023 USD ($)
Operating Leases
2024	$ 1,454,919
2025	953,677
2026	621,696
2027	397,469
2028	99,432
Total lease payments	3,527,193
Less: Interest	(242,021)
Present value of lease liabilities	3,285,172
Finance Leases
2024	420,368
2025	212,098
2026	114,141
Total lease payments	746,607
Less: Interest	(58,443)
Present value of lease liabilities	$ 688,164

Leases - Summary of Weighted Av

Leases - Summary of Weighted Average Assumptions on Lease Term and Discount Rate and Supplemental Cash Flow Information Related to Leases (Details)	12 Months Ended
	Jun. 30, 2023 USD ($)
Lessee Disclosure [Abstract]
Operating lease remaining lease term	3 years 1 month 6 days
Operating lease discount rate	4.14%
Finance lease remaining lease term	9 months 18 days
Finance lease discount rate	6.69%
Cash paid for operating leases	$ 1,449,629
Cash paid for finance leases	$ 624,863

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue Recognition [Line Items]
Maximum term of payments for transfer goods and services	1 year
Unbilled receivables	$ 203,222
Bad debt expense	11,659	$ 216,466
Revenue recognized	600,000	300,000
Revenue	73,521,291	71,354,298
Seed Sales
Revenue Recognition [Line Items]
Revenue	$ 72,808,112	69,425,407
ADAMA Collaboration Agreement
Revenue Recognition [Line Items]
Total share value percentage	60%
Share net settlement amount pursuant to the collaboration agreement	$ 500,000
ADAMA Collaboration Agreement | Seed Sales
Revenue Recognition [Line Items]
Revenue	$ 6,500,000	$ 2,400,000
ADAMA Collaboration Agreement | Makhteshim Agan of North America, Inc.
Revenue Recognition [Line Items]
Total share value percentage	40%
Minimum
Revenue Recognition [Line Items]
Term of customer invoice payment	30 days
Maximum
Revenue Recognition [Line Items]
Term of customer invoice payment	180 days
Maximum | ADAMA Collaboration Agreement
Revenue Recognition [Line Items]
Total share value percentage	100%

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Total revenue	$ 73,521,291	$ 71,354,298
Seed Sales
Disaggregation Of Revenue [Line Items]
Total revenue	72,808,112	69,425,407
Services
Disaggregation Of Revenue [Line Items]
Total revenue	$ 713,179	$ 1,928,891

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 29, 2020	Jun. 30, 2023	Jun. 30, 2022
Goodwill And Intangible Assets [Line Items]
Goodwill acquire transaction			$ 0
Goodwill impairment charges		$ 0	1,548,324
Impairment charge on intangible assets		0	0
Amortization expense		$ 2,266,609	$ 2,401,376
Pasture Genetics
Goodwill And Intangible Assets [Line Items]
Goodwill acquire transaction	$ 1,452,436

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Activity of Goodwill (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 0	$ 1,651,634
Goodwill additions		0
Goodwill Impairment	$ 0	(1,548,324)
Goodwill currency translation adjustment		(103,310)
Goodwill, Ending Balance		$ 0

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Finite Lived Intangible Assets [Line Items]
Intangible asset	$ 34,095,827	$ 37,130,942
Intangible addition	(1,885,907)	0
Intangible amortization expense	(2,266,609)	(2,401,376)
Intangible currency translation adjustment	(210,452)	(633,739)
Intangible asset	29,732,859	34,095,827
Trade Name
Finite Lived Intangible Assets [Line Items]
Intangible asset	1,084,791	1,310,489
Intangible addition	0	0
Intangible amortization expense	(196,627)	(203,009)
Intangible currency translation adjustment	(7,231)	(22,689)
Intangible asset	880,933	1,084,791
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Intangible asset	5,499,815	6,302,591
Intangible addition	0	0
Intangible amortization expense	(353,000)	(373,393)
Intangible currency translation adjustment	(178,140)	(429,383)
Intangible asset	4,968,675	5,499,815
Non-compete
Finite Lived Intangible Assets [Line Items]
Intangible asset	0	5,058
Intangible addition		0
Intangible amortization expense		(5,058)
Intangible currency translation adjustment		0
Intangible asset		0
GI Customer list
Finite Lived Intangible Assets [Line Items]
Intangible asset	42,983	50,146
Intangible addition	0	0
Intangible amortization expense	(7,164)	(7,163)
Intangible currency translation adjustment	0	0
Intangible asset	35,819	42,983
Supply Agreement
Finite Lived Intangible Assets [Line Items]
Intangible asset	775,241	850,874
Intangible addition	0	0
Intangible amortization expense	(75,633)	(75,633)
Intangible currency translation adjustment	0	0
Intangible asset	699,608	775,241
Grower Relationships
Finite Lived Intangible Assets [Line Items]
Intangible asset	1,331,581	1,436,988
Intangible addition	0	0
Intangible amortization expense	(105,406)	(105,407)
Intangible currency translation adjustment	0	0
Intangible asset	1,226,175	1,331,581
Intellectual Property
Finite Lived Intangible Assets [Line Items]
Intangible asset	23,035,925	24,427,857
Intangible addition	0	0
Intangible amortization expense	1,385,391	1,391,932
Intangible currency translation adjustment	0	0
Intangible asset	21,650,534	23,035,925
License Agreements
Finite Lived Intangible Assets [Line Items]
Intangible asset	1,986,598	2,340,269
Intangible addition	(1,885,907)	0
Intangible amortization expense	(75,610)	(172,004)
Intangible currency translation adjustment	(25,081)	(181,667)
Intangible asset	0	1,986,598
Internal use software
Finite Lived Intangible Assets [Line Items]
Intangible asset	338,893	406,670
Intangible addition	0	0
Intangible amortization expense	(67,778)	(67,777)
Intangible currency translation adjustment	0	0
Intangible asset	$ 271,115	$ 338,893

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Intangible Assets (Future Amortization) (Details)	Jun. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 2,179,262
2025	2,139,453
2026	2,025,950
2027	1,921,799
2028	1,864,508
Thereafter	$ 19,601,887

Property, Plant and Equipment -

Property, Plant and Equipment - Components of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 18,299,941	$ 27,105,768
Less: accumulated depreciation	(8,217,773)	(10,234,099)
Property, plant and equipment, net	10,082,168	16,871,669
Land and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	939,089	2,265,087
Buildings and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	3,356,755	8,119,960
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	12,667,858	14,972,462
Vehicles
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	605,891	1,085,342
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	552,810	552,810
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 177,538	$ 110,107

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details)		12 Months Ended
	Jun. 20, 2023 USD ($) Acres	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Depreciation expense		$ 1,997,118	$ 2,433,319
AgAmerica | Secured Real Estate Note
Property, Plant and Equipment [Line Items]
Debt face amount	$ 4,300,000
Number of acres of land held as security | Acres	31

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($)			3 Months Ended	5 Months Ended	6 Months Ended	12 Months Ended		44 Months Ended
	Feb. 06, 2023	Dec. 23, 2022	Mar. 31, 2022	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]
Equity method investments				$ 23,059,705		$ 23,059,705	$ 367,970
Gain on sale of equity investment						32,030	0
Gain on sale of business interest						38,167,102	0
Net proceeds from sale of equity investment						400,000	988,504
Capital contributions to partnerships						172,917	0
Intangible asset				29,732,859		29,732,859	34,095,827	$ 37,130,942
Revenue						73,521,291	71,354,298
Shell
Schedule of Equity Method Investments [Line Items]
Proceeds from divestiture of business at closing	$ 7,000,000
Membership interest repurchase percent	6%
Fair market value of purchase option	$ 700,000
Cash	7,000,000
Shell | Minimum
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase price	7,100,000
Shell | Maximum
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase price	12,000,000
Additional proceeds to be received from sale of businesses in one year				6,000,000
Conterra
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	6,600,000				$ 400,000		$ 400,000	$ 3,100,000
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Equity method investments	$ 23,400,000			22,307,486		$ 22,307,486
Costs from contract with customer excluding assessed tax				$ 200,000
Additional ownership percentage	10%
Fair value of contingent transfers	$ 500,000
Ownership interest	34%			34%		34%	0%
Carrying value of asset and inventory contributed	$ 5,500,000
Fair value of property contributed to llc	12,900,000
Net identifiable assets	19,300,000
Difference between carrying amount and net identifiable assets	4,100,000
Deconsolidation revaluation of retained investment, gain amount	8,000,000
Intangible asset				$ 18,600,000		$ 18,600,000
Revenue				300,000
Right to extend contract at business agreement						The Company has the right to extend the contract for a second year.
Vision Bioenergy | Shell
Schedule of Equity Method Investments [Line Items]
Equity method investments	23,396,832
Gain on sale of business interest	38,167,102
Proceeds from divestiture of business at closing	$ 7,000,000
Membership interest repurchase percent	6%
Fair market value of purchase option	$ 695,000					$ 695,000
Ownership interest	66%
Carrying value of asset and inventory contributed	$ 5,532,694			5,532,694		5,532,694
Contribution made in exchange for ownership interest	13,200,000
Cash	7,000,000
Fair value of payment based on discounted value	5,700,000			5,747,127		5,747,127
Additional payments made to partnership in exchange for ownership interest	12,000,000
Fair value of additional cash contribution based on discounted value				11,700,000		11,700,000
Member investment in partnership	45,400,000
Aggregate consideration received	43,700,000
Equity method investment total valuation amount	68,800,000
Fair value of intangible contributed to llc	19,200,000
Vision Bioenergy | Shell | Notes Receivable, Net
Schedule of Equity Method Investments [Line Items]
Fair value of payment based on discounted value				5,800,000		5,800,000
Vision Bioenergy | Shell | Maximum
Schedule of Equity Method Investments [Line Items]
Additional proceeds to be received from sale of businesses in one year	6,000,000
Possible reduction in proceeds to be received from sale of businesses in one year	4,500,000
Vision Bioenergy | Conterra
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	6,900,000
Vision Bioenergy | Conterra | Shell
Schedule of Equity Method Investments [Line Items]
Settlement of long-term debt principal, interest and other related costs	$ 6,860,838					6,860,838
Trigall Australia Pty Ltd
Schedule of Equity Method Investments [Line Items]
Equity method investments		$ 800,000		$ 752,219		752,219
Gain on sale of equity investment		1,800,000
Additional proceeds to be received from sale of businesses in one year		$ 1,000,000
Capital contributions to partnerships						$ 200,000
Ownership interest		20%		20%		20%	0%
Proceeds from sale of interest in subsidiary		$ 2,000,000
Fair value of assets contributed		3,800,000
Capital contributions to be made		600,000
Carrying value of asset and inventory contributed		2,000,000
Trigall Australia Pty Ltd | Promissory Note
Schedule of Equity Method Investments [Line Items]
Promisory notes to be recieved		1,000,000
Trigall Australia Pty Ltd | Notes Receivable, Net | Promissory Note
Schedule of Equity Method Investments [Line Items]
Proceeds from partnership transaction		1,000,000
Trigall Australia Pty Ltd | Trigall Genetic S.A
Schedule of Equity Method Investments [Line Items]
Equity method investments		$ 3,000,000
Ownership interest		80%
Fair value of assets contributed		$ 3,800,000
Bioceres
Schedule of Equity Method Investments [Line Items]
Equity method investments							$ 367,970
Gain on sale of equity investment						$ 32,030
Percentage of sale of investment in Bioceres, S.A.			71.40%
Net proceeds from sale of equity investment			$ 1,000,000			$ 400,000
Gain on sale of marketable security			$ 100,000
Ownership interest				0%		0%	1%

Investments - Schedule of Gain

Investments - Schedule of Gain on Equity Method Investments (Details) - USD ($)			5 Months Ended	6 Months Ended	12 Months Ended		44 Months Ended
	Jun. 30, 2023	Feb. 06, 2023	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]
Equity investment	$ 23,059,705		$ 23,059,705		$ 23,059,705	$ 367,970
Notes receivable, net	6,846,897		6,846,897		6,846,897	0
Gain on equity method investments					38,167,102	0
Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement		$ 6,600,000		$ 400,000		$ 400,000	$ 3,100,000
Shell
Schedule of Equity Method Investments [Line Items]
Cash		7,000,000
Fair value of 6% member purchase option		700,000
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Equity investment	22,307,486	23,400,000	22,307,486		22,307,486
Fixed assets and inventory transfer		(5,500,000)
Vision Bioenergy | Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement		6,900,000
Vision Bioenergy | Shell
Schedule of Equity Method Investments [Line Items]
Equity investment		23,396,832
Cash		7,000,000
Notes receivable, net	5,800,000	5,700,000	5,747,126
Fair value of 6% member purchase option		695,000			695,000
Fixed assets and inventory transfer	$ (5,532,694)	(5,532,694)	$ (5,532,694)		(5,532,694)
Gain on equity method investments		38,167,102
Vision Bioenergy | Shell | Conterra
Schedule of Equity Method Investments [Line Items]
Debt retirement		$ 6,860,838			$ 6,860,838

Investments - Schedule of Gai_2

Investments - Schedule of Gain on Equity Method Investments (Parenthetical) (Details) - Shell	Feb. 06, 2023
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase percent	6%
Vision Bioenergy Oilseeds LLC [Member]
Schedule of Equity Method Investments [Line Items]
Membership interest repurchase percent	6%

Investments - Summary of Financ

Investments - Summary of Financial Information of Unaudited Balance Sheet (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]
Cash	$ 3,398,793	$ 2,056,508
Intangible assets	29,732,859	34,095,827	$ 37,130,942
Goodwill		0	1,651,634
Other assets	2,066,081	1,128,507
TOTAL ASSETS	151,989,828	133,787,851
Current liabilities	71,290,883	48,291,496
Equity	68,823,433	51,408,669	$ 74,393,193
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	151,989,828	$ 133,787,851
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Cash	8,973,896
Other current assets	747,090
Fixed assets	15,051,799
Intangible assets	18,575,108
Goodwill	11,870,376
Other assets	255,899
TOTAL ASSETS	55,474,168
Current liabilities	1,381,493
Long-term liabilities	176,203
Equity	53,916,472
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY	$ 55,474,168

Investments - Summary of Fina_2

Investments - Summary of Financial Information of Unaudited Income Statement (Details) - USD ($)	5 Months Ended	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Revenue		$ 73,521,291	$ 71,354,298
Gross profit (loss)		14,538,081	6,355,162
Loss from operations		(17,943,522)	(32,803,767)
Net loss		$ 14,410,078	$ (36,395,350)
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Revenue	$ 168,977
Gross profit (loss)	(726,502)
Loss from operations	(3,358,348)
Net loss	$ (3,203,958)

Investments - Schedule of Carry

Investments - Schedule of Carrying Amount of The Company's Equity Method Investments (Details) - USD ($)	Jun. 30, 2023	Feb. 06, 2023	Dec. 23, 2022	Jun. 30, 2022
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 23,059,705			$ 367,970
Vision Bioenergy
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 22,307,486	$ 23,400,000
Economic Interest	34%	34%		0%
Trigall Australia
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount	$ 752,219		$ 800,000
Economic Interest	20%		20%	0%
Bioceres
Schedule of Equity Method Investments [Line Items]
Total equity method investments, Carrying Amount				$ 367,970
Economic Interest	0%			1%

Debt - Schedule of Total Debt O

Debt - Schedule of Total Debt Outstanding (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	$ 44,900,779	$ 12,678,897
Long-term portion of working capital lines of credit, less current portion
Total working capital lines of credit, net	44,900,779	34,382,183
Current portion of long-term debt
Finance leases, Current	$ 383,403	$ 804,309
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total current portion, net	Total current portion, net
Total current portion, net	$ 3,808,761	$ 8,316,783
Long-term debt, less current portion
Finance leases, Noncurrent	$ 304,761	$ 500,723
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-Term Debt and Lease Obligation	Long-Term Debt and Lease Obligation
Debt issuance costs, Noncurrent	$ (191,245)	$ (21)
Total long-term portion, net	4,499,334	3,992,540
Total debt, net	8,308,095	12,309,323
CIBC
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	19,335,427	12,804,611
National Australia Bank Limited
Current portion of working capital lines of credit
Total current portion of working capital lines of credit, net	25,938,839	338,314
Long-term portion of working capital lines of credit, less current portion
Total long-term portion of working capital lines of credit		21,703,286
CIBC and NAB
Current portion of long-term debt
Debt issuance costs, Current	(373,487)	(464,028)
Term Loan Long Term Current | National Australia Bank Limited
Current portion of long-term debt
Secured Debt, Current	2,318,050	344,400
Machinery & Equipment Loans Long Term Current | National Australia Bank Limited
Current portion of long-term debt
Secured Debt, Current	1,141,349	246,547
Machinery & Equipment Loans Long Term Current | Hyster
Current portion of long-term debt
Secured Debt, Current	11,902	11,834
Vehicle Loans | Ford Credit
Current portion of long-term debt
Secured Debt, Current	51,278	40,341
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	70,103	88,583
Rooster RE Short
Current portion of long-term debt
Secured Debt, Current	0	6,905,995
Debt issuance costs, Current	(97,221)	(36,643)
Term Loan Long Term Non Current | National Australia Bank Limited
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent		2,410,800
Machinery & Equipment Loans long Term | National Australia Bank Limited
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent		963,733
Machinery & Equipment Loans long Term | Hyster
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	15,715	28,722
AgAmerica RE Long
Long-term debt, less current portion
Secured Long-term Debt, Noncurrent	$ 4,300,000	$ 0

Debt - CIBC Credit Facility - A

Debt - CIBC Credit Facility - Additional Information (Details) - USD ($) $ in Millions						12 Months Ended
	Mar. 22, 2023	Dec. 23, 2022	Oct. 28, 2022	May 13, 2022	Dec. 26, 2019	Jun. 30, 2023	Sep. 22, 2022
Line Of Credit Facility [Line Items]
Incurred financing charges associated other lenders totaled						$ 1.5
Line of credit facility, remaining borrowing capacity						1
CIBC
Line Of Credit Facility [Line Items]
Line of credit and security agreement date					Dec. 26, 2019
Line of credit facility, maximum borrowing capacity					$ 35	$ 25
Borrowing base value of an eligible inventory sublimit			$ 12	$ 9
Debt instrument, maturity date		Mar. 23, 2023			Dec. 23, 2022	Aug. 31, 2024
Line of credit facility, borrowing capacity, description						Availability of funds under the Amended CIBC Credit Facility is subject to a borrowing base of up to 85% of eligible domestic accounts receivable (90% of eligible foreign accounts receivable) plus up to the lesser of (i) 65% of eligible inventory, (ii) 85% of the appraised net orderly liquidation value of eligible inventory
Debt instrument, debt default, Increase in interest rate per annum	2%
Line of credit facility, current borrowing capacity						$ 20.2
Increase in line of credit facility						4.8
Line of credit facility, remaining borrowing capacity						$ 0.8
CIBC | Loan Agreement
Line Of Credit Facility [Line Items]
Debt instrument, maturity date	Aug. 31, 2024
CIBC | Line of Credit
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 21	$ 18
Debt instrument, interest rate						10.25%
Minimum potential liquidity raised to meet covenant compliance							$ 1
CIBC | Line of Credit | Federal Funds Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	0.50%
CIBC | Line of Credit | Prime Rate
Line Of Credit Facility [Line Items]
Basis spread on variable rate	2%
CIBC | Maximum
Line Of Credit Facility [Line Items]
Borrowing base in percentage based on eligible domestic accounts receivable	85%
Borrowing base in percentage based on eligible foreign accounts receivable	90%
Borrowing base in percentage based on eligible inventory	65%
Borrowing base in percentage based on liquidation value of the inventory, subject to lender reserves	85%
CIBC | February 1 to October 31 of Each Year
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 25
CIBC | November 1 to January 31 of Each Year
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 18

Debt - NAB Facilities - Additio

Debt - NAB Facilities - Additional Information (Details)		1 Months Ended	12 Months Ended
	Oct. 25, 2022 AUD ($)	May 31, 2023 AUD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 AUD ($)	Jan. 11, 2023 USD ($)	Dec. 31, 2022 AUD ($)	Jun. 30, 2022 USD ($)	Nov. 11, 2021 AUD ($)
Line Of Credit Facility [Line Items]
Line of credit facility, remaining borrowing capacity			$ 1,000,000
Facility outstanding amount			$ 44,900,779					$ 34,382,183
Term Loan
Line Of Credit Facility [Line Items]
Line of credit facility interest accrued			8.607%		8.607%
Facility outstanding amount			$ 2,600,000		$ 4,000,000
Line of credit facility, Principal payments		$ 500,000
Line of credit facility principal payment start date			May 31, 2023	May 31, 2023
Line of credit facility, termination date			Mar. 31, 2026	Mar. 31, 2026
Line of credit facility, floating interest rate during period			2.60%	2.60%
Line of credit facility, interest rate description			Monthly interest amounts outstanding under the Term Loan are payable in arrears at a floating rate quoted by NAB for the applicable pricing period, plus 2.6%.	Monthly interest amounts outstanding under the Term Loan are payable in arrears at a floating rate quoted by NAB for the applicable pricing period, plus 2.6%.
Master Asset Finance Facility
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 2,000,000		3,000,000
Line of credit facility, remaining borrowing capacity			200,000		300,000
Line of credit facility, current borrowing capacity			26,100,000		39,400,000
Facility outstanding amount			$ 1,100,000		1,700,000
Net due from related entities covenant maximum	$ 25,000,000					$ 18,500,000
Debt instrument maturity year			2029	2029
Master Asset Finance Facility | Minimum
Line Of Credit Facility [Line Items]
Interest rate			2.86%	2.86%
Master Asset Finance Facility | Maximum
Line Of Credit Facility [Line Items]
Interest rate			6.82%	6.82%
National Australia Bank Limited
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 9,900,000		15,000,000
National Australia Bank Limited | Borrowing Base Line
Line Of Credit Facility [Line Items]
Line of credit facility, expiration extended period	1 year
Line of credit facility, termination date	Sep. 30, 2024
National Australia Bank Limited | Borrowing Base Line | Minimum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			21,200,000						$ 32,000,000
National Australia Bank Limited | Borrowing Base Line | Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			26,500,000				$ 40,000,000
National Australia Bank Limited | Overdraft Credit
Line Of Credit Facility [Line Items]
Line of credit facility, expiration extended period	1 year
Line of credit facility, termination date	Sep. 29, 2023
National Australia Bank Limited | Overdraft Credit | Minimum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			700,000						$ 1,000,000
National Australia Bank Limited | Overdraft Credit | Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 2,000,000		1,300,000
National Australia Bank Limited | Master Asset Finance Facility
Line Of Credit Facility [Line Items]
Line of credit facility, expiration extended period	1 year
Line of credit facility, termination date	Sep. 29, 2023
National Australia Bank Ltd Facility
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			32,500,000		49,000,000
Increase in line of credit facility			$ 1,700,000	$ 2,600,000
Interest rate			1.65%	1.65%
National Australia Bank Ltd Facility | Maximum
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 27,800,000		42,000,000
National Australia Bank Ltd Facility | Borrowing Base Line
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 26,500,000		$ 40,000,000
Line of credit facility interest accrued			8.21%		8.21%
National Australia Bank Ltd Facility | Line of Credit
Line Of Credit Facility [Line Items]
Net due from related entities covenant maximum	$ 25,000,000
National Australia Bank Ltd Facility | Overdraft Facility
Line Of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 1,300,000		$ 2,000,000
Line of credit facility interest accrued			9.47%		9.47%

Debt - AgAmerica Note - Additio

Debt - AgAmerica Note - Additional Information (Details) - AgAmerica - Secured Real Estate Note $ in Millions	Jun. 20, 2023 USD ($) Acres	Jun. 30, 2023
Line of Credit Facility [Line Items]
Number of acres of land held as security | Acres	31
Debt face amount | $	$ 4.3
Debt instrument, maturity date	Jun. 20, 2026
Debt instrument, annual interest rate		9.94%
Debt instrument, late fee percentage	5%
Debt instrument, threshold period of periodic payment for late fee	10 days
Threshold period of periodic payment for additional interest rate	30 days
Debt instrument, additional interest rate on delinquent periodic payments	5%
Debt Instrument, prepayment premium percentage	1%
SOFR
Line of Credit Facility [Line Items]
Basis spread on variable rate	4.85%

Debt - Rooster Note - (Addition

Debt - Rooster Note - (Additional Information) (Details) - Conterra - USD ($) $ in Millions				1 Months Ended	6 Months Ended	12 Months Ended	44 Months Ended
	Feb. 06, 2023	Dec. 23, 2022	Sep. 22, 2022	Nov. 30, 2017	Dec. 31, 2022	Jun. 30, 2022	Jun. 30, 2021
Line of Credit Facility [Line Items]
Debt face amount				$ 2.1
Debt instrument, interest rate		9.25%		7.75%
Debt instrument, maturity date		Mar. 01, 2023	Dec. 23, 2022
Debt retirement	$ 6.6				$ 0.4	$ 0.4	$ 3.1
Secured Promissory Notes
Line of Credit Facility [Line Items]
Gross proceeds from issuance of long term debt				$ 12.5
Secured Real Estate Note
Line of Credit Facility [Line Items]
Debt face amount				$ 10.4
Debt instrument, interest rate				7.75%

Debt - MFP Loan Agreement (Addi

Debt - MFP Loan Agreement (Additional Information) (Details) - USD ($) $ in Millions	Mar. 22, 2023	Dec. 23, 2022	Oct. 28, 2022	Sep. 22, 2022
Standby Letters of Credit
Line of Credit Facility [Line Items]
Debt face amount			$ 12	$ 9
Debt instrument, maturity date	Sep. 30, 2024	Apr. 30, 2023	Sep. 30, 2024	Jan. 23, 2023
Line of credit facility, maximum borrowing capacity			$ 13
Line of credit facility, unused capacity commitment fee percentage	4.25%			3.50%
MFP Loan Agreement
Line of Credit Facility [Line Items]
Debt instrument, maturity date	Mar. 30, 2025
Line of credit facility, maximum borrowing capacity			$ 12	$ 9
Line of credit facility, unused capacity commitment fee percentage				3.50%
Debt instrument, percentage of interest payable in cash				50%
Debt instrument, percentage of interest paid in kind				50%
MFP Loan Agreement | Reference Rate Floor
Line of Credit Facility [Line Items]
Debt instrument, interest rate				1.25%
MFP Loan Agreement | SOFR
Line of Credit Facility [Line Items]
Basis spread on variable rate				9.25%
MFP Loan Agreement | Maximum
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 13
MFP Loan Agreement | Letter of Credit
Line of Credit Facility [Line Items]
Debt instrument, maturity date				Jan. 23, 2023

Debt - Schedule of Annual Matur

Debt - Schedule of Annual Maturities of Short-Term and Long-Term Debt (Details)	Jun. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2024	$ 3,522,579
2025	75,904
2026	4,309,914
Total	$ 7,908,397

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
United States	$ 20,631,632	$ (37,346,576)
Foreign	(5,707,581)	1,437,493
Income (loss) before income taxes	$ 14,924,051	$ (35,909,083)

Income Taxes - Components of Pr

Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Current:
State	$ 12,431	$ 301
Foreign	42,480	266,129
Total current provision	54,911	266,430
Deferred:
Federal	0	(1)
Foreign	(818,550)	146,994
Total deferred provision	(818,550)	146,993
Provision for (benefit from) income taxes	$ (763,639)	$ 413,423

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Provision and Expected Income Tax Computed Using U.S. Federal Income Tax Rate (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Tax benefit at statutory tax rate	$ 3,134,080	$ (7,540,908)
State benefit, net of federal benefit	388,572	(493,262)
Estimated GILTI Inclusion	267,352	0
Federal and state research credits - current year	67,144	(390,235)
Other permanent differences	(187,808)	184,725
Foreign rate differential	(521,188)	420,829
Goodwill impairment	0	549,577
Valuation allowance	(5,371,275)	7,573,300
Transfer Pricing Adjustments	1,380,810	0
Stock Compensation	266,127	0
Equity method investments	(277,952)	0
Other	90,499	109,397
Provision for (benefit from) income taxes	$ (763,639)	$ 413,423

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Deferred tax assets:
Net operating loss carry forwards	$ 21,170,710	$ 22,815,372
Tax credit carry forwards	2,184,461	1,388,106
Allowance for bad debts	1,184,158	1,216,187
Goodwill	1,688,905	1,597,873
Lease liability	880,955	1,187,090
Interest expense carryforwards	1,446,422	1,144,535
Other, net	2,588,490	1,756,460
Total deferred tax assets	31,144,101	31,105,623
Valuation allowance for deferred tax assets	(22,061,576)	(27,437,845)
Deferred tax assets, net of valuation allowance	9,082,525	3,667,778
Deferred tax liabilities:
ROU lease asset	(903,508)	(1,226,879)
Equity method investments	(4,620,682)	0
Intangible assets	(1,910,044)	(1,381,955)
Fixed assets	(1,160,228)	(1,382,821)
Total deferred tax liabilities	(8,594,462)	(3,991,655)
Net deferred tax asset	$ 488,063
Net deferred tax liability		$ (323,877)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Line Items]
Deferred tax assets, decrease in valuation allowance	$ 5,400,000
Transactions increase in ownership, period	3 years
Interest limitation carryovers	$ 6,600,000
Undistributed earnings of foreign subsidiaries	2,300,000
Unrecognized tax benefits	76,919	$ 77,350	$ 79,341
Unrecognized tax benefits that, if recognized, would reduce annual effective tax rate	100,000
Accrued interest and penalties associated with uncertain tax positions	0	$ 0
Unrecognized tax benefits to change significantly	0
Federal
Income Tax Disclosure [Line Items]
Net operating loss carried forward anual limitations	17,100,000
Operating loss carryforwards	$ 92,500,000
Operating loss carryforwards, expiration dates	Jun. 30, 2031
Net operating loss carried forward indefinitely	$ 72,800,000
Research and development tax credit carryforwards	$ 1,400,000
Research tax credit carryforwards, expiration dates	Jun. 30, 2031
Foreign tax credit carryforwards	$ 200,000
Foreign tax credit carryforwards, expiration dates	Jun. 30, 2023
State
Income Tax Disclosure [Line Items]
Operating loss carryforwards	$ 32,100,000
Operating loss carryforwards, expiration dates	Jun. 30, 2031
Research and development tax credit carryforwards	$ 25,089
Australian
Income Tax Disclosure [Line Items]
Research and development tax credit carryforwards	$ 700,000
Minimum
Income Tax Disclosure [Line Items]
Percentage of transactions increase in ownership of certain stockholders	50%

Income Taxes - Summarized Activ

Income Taxes - Summarized Activity Related to Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning Balance	$ 77,350	$ 79,341
Other	(431)	(1,991)
Ending Balance	$ 76,919	$ 77,350

Foreign Currency Contracts - Ad

Foreign Currency Contracts - Additional Information (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Foreign Currency Contracts [Line Items]
Foreign exchange contract liability	$ 849,033	$ 996,106
Gains (losses) on foreign exchange contracts	(859,696)	(777,913)
Options intrinsic value	0
Prepaid Expenses and Other Current Assets
Foreign Currency Contracts [Line Items]
Option premiums value	5,891
Foreign Currency Forward Contracts
Foreign Currency Contracts [Line Items]
Foreign currency forward contracts, notional value	9,561,155
Gains (losses) on foreign exchange contracts	123,703	$ (958,373)
Foreign Currency Options
Foreign Currency Contracts [Line Items]
Foreign currency forward contracts, notional value	$ 7,400,000
Minimum | Foreign Currency Forward Contracts
Foreign Currency Contracts [Line Items]
Foreign currency maturity term	2023-07
Maximum | Foreign Currency Forward Contracts
Foreign Currency Contracts [Line Items]
Foreign currency maturity term	2023-10

Equity - Additional Information

Equity - Additional Information (Details) - USD ($)					12 Months Ended
	Mar. 22, 2023	Oct. 28, 2022	Sep. 22, 2022	Sep. 23, 2020	Jun. 30, 2023	Jun. 30, 2022	Dec. 22, 2022	May 17, 2022	Sep. 27, 2021
MFP Loan Agreement
Class Of Stock [Line Items]
Warrants to purchase of common stock	1,300,000	166,700	500,000		2,633,400		666,700
Warrant exercise price per share	$ 2.15	$ 1.6	$ 1.6
Warrant expiration term	5 years	5 years	5 years
Warrants capitalized					$ 1,894,901
Interest expense amortized					860,758
ATM Agreement | B. Riley Securities, Inc
Class Of Stock [Line Items]
Maximum aggregate offering price of common stock by agent				$ 14,000,000				$ 24,600,000	$ 17,100,000
Percentage of commission on gross proceeds from sale of common stock through agent				3.50%
Gross proceeds from sale of common stock					$ 200,000	$ 7,400,000
Number of common stock shares issued during the period					102,455	3,655,136
Value of remaining common stock available to sell under agreement					$ 6,200,000

Equity-Based Compensation - Add

Equity-Based Compensation - Additional Information (Details) - USD ($)

1 Months Ended

12 Months Ended

Jan. 31, 2019

Jun. 30, 2023

Jun. 30, 2022

Dec. 31, 2020

Oct. 31, 2020

Jan. 16, 2019

Dec. 31, 2015

Sep. 30, 2015

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Oct. 31, 2012

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Options granted

1,389,675

Exercise price, lower range limit

$ 0.81

Exercise price, upper range Limit

$ 1.89

Stock-based compensation

$ 1,932,415

$ 2,267,186

Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock options, term

10 years

Restricted Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock-based compensation, total compensation cost not yet recognized, period for recognition

1 year 5 months 4 days

Number of restricted stock units issued

534,628

304,421

Fair value of awards granted

$ 608,618

$ 846,080

Stock-based compensation

1,932,416

$ 982,422

Unrecognized stock compensation expense related to restricted stock grants

$ 362,281

Maximum | Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

3 years

Maximum | Restricted Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

3 years

Minimum | Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

1 year

Minimum | Restricted Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

1 year

2009 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of shares available for issuance of grants

350,343

2,450,000

2,450,000

1,700,000

1,700,000

1,250,000

1,250,000

Options granted

1,143,447

Stock options granted and outstanding, weighted average grant date fair value

$ 0.69

Unrecognized stock compensation expense, net of estimated forfeitures, related to options

$ 944,925

Stock-based compensation, total compensation cost not yet recognized, period for recognition

1 year 5 months 19 days

2009 Plan | Maximum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock options, term

10 years

2009 Plan | Minimum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock options, term

5 years

Voting stock, percentage

10%

Fair market value of common stock, percentage

110%

2019 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of shares available for issuance of grants

2,750,000

1,646,522

4,000,000

4,000,000

Number of shares reserved for issuance under the plan

8,243,790

Number of new shares

4,000,000

Equity-Based Compensation - Sch

Equity-Based Compensation - Schedule of Weighted Average Assumptions (Details) - Stock Options	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk free rate, minimum	2.90%	0.80%
Risk free rate, maximum	4.40%	2.80%
Volatility, minimum	64.70%	61.70%
Volatility, maximum	66.10%	64.70%
Forfeiture rate	9.10%	3.20%

Equity-Based Compensation - Sum

Equity-Based Compensation - Summary Of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]
Options, Outstanding as of beginning of period	4,637,100	3,776,568
Options, Granted	1,389,675	994,725
Options, Exercised	(2,100)	(38,774)
Options, Canceled/forfeited/expired	(947,707)	(95,419)
Options, Outstanding as of end of period	5,076,968	4,637,100	3,776,568
Options, vested and exercisable at end of period	3,685,678
Options, vested and expected to vest	5,066,581
Weighted-Average Exercise Prices, Outstanding as of beginning of period	$ 2.64	$ 2.65
Weighted-Average Exercise Prices, Granted	1.25	2.63
Weighted-Average Exercise Prices, Exercised	0.95	2.33
Weighted-Average Exercise Prices, Canceled/forfeited/expired	2.84	2.82
Weighted-Average Exercise Prices, Outstanding as of end of period	2.23	$ 2.64	$ 2.65
Weighted-Average Exercise Prices, vested and exercisable	2.47
Weighted-Average Exercise Price, vested and expected to vest	$ 2.23
Options Outstanding, Weighted-Average Remaining Contractual Term (in years)	7 years 1 month 6 days	6 years 7 months 6 days	8 years
Weighted-Average Remaining Contractual Term (in years), vested and exercisable	6 years 3 months 18 days
Weighted-Average Remaining Contractual Term (in years), vested and expected to vest	7 years 1 month 6 days
Options, Outstanding, Aggregate Intrinsic Value	$ 292,079		$ 3,962,766
Options, vested and exercisable, Aggregate Intrinsic Value	59,669
Options, vested and expected to vest, Aggregate Intrinsic Value	$ 289,227

Equity-Based Compensation - S_2

Equity-Based Compensation - Summary of Activity Related to Non-Vested Restricted Stock Units (Details) - Restricted Stock Units - $ / shares	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Nonvested Restricted Stock Units Outstanding, Beginning	267,919	361,570
Number of Nonvested Restricted Stock Units, Granted	534,628	304,421
Number of Nonvested Restricted Stock Units, Vested	(353,649)	(391,036)
Number of Nonvested Restricted Stock Units, Forfeited	(8,750)	(7,036)
Number of Nonvested Restricted Stock Units Outstanding, Ending	440,148	267,919	361,570
Weighted-Average Grant Date Fair Value, Beginning	$ 2.66	$ 2.51
Weighted-Average Grant Date Fair Value, Granted	1.14	2.78
Weighted-Average Grant Date Fair Value, Vested	2.22	2.62
Weighted-Average Grant Date Fair Value, Forfeited	2.5	2.35
Weighted-Average Grant Date Fair Value, Ending	$ 1.17	$ 2.66	$ 2.51
Weighted-Average Remaining Contractual Life (Years)	1 year 4 months 24 days	1 year 2 months 12 days	1 year 3 months 18 days
Weighted-Average Remaining Contractual Life (Years), Granted	1 year 6 months

Series B Convertible Preferre_3

Series B Convertible Preferred Stock - Additional Information (Details) - USD ($)			12 Months Ended		16 Months Ended
	Feb. 18, 2022	Sep. 27, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023
Temporary Equity [Line Items]
Common stock, par value			$ 0.001	$ 0.001	$ 0.001
Net proceeds from sale of common stock			$ 128,778	$ 11,777,690
Fair value of Series B Preferred Stock				4,638,521
Dividends accrued			365,979	127,541
Accretion of discount for warrants			$ 103,350	$ 38,757
Series B Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred stock, shares issued			1,695	1,695	1,695
Preferred stock, par value			$ 0.001	$ 0.001	$ 0.001
Dividends accrued					$ 493,520
Accretion of discount for warrants					$ 142,107
Series B Convertible Preferred Stock | Purchase Agreement
Temporary Equity [Line Items]
Preferred stock, shares issued	1,695
Preferred stock, par value	$ 0.001
Net proceeds from sale of common stock		$ 6,200,000
Warrant exercise price per share	$ 5
Fair value of Series B Preferred Stock			$ 4,638,521
Initial term of temporary equity issuance of preferred stock.			42 months
Accreted to its redemption value			$ 5,000,250
Series B Convertible Preferred Stock | Purchase Agreement | Minimum
Temporary Equity [Line Items]
Percentage of cash dividends	5%
Series B Convertible Preferred Stock | Purchase Agreement | Maximum
Temporary Equity [Line Items]
Percentage of cash dividends	7%
Series B Convertible Preferred Stock | Common Stock | Purchase Agreement
Temporary Equity [Line Items]
Warrants to purchase of common stock	559,350
Common stock, par value	$ 0.001
Unit price	$ 2,950
Net proceeds from sale of common stock	$ 5,000,000
Convertible preferred stock into common stock	1,000
Percentage of common stock outstanding shares	19.99%
Preferred stock, issuable upon conversion	7,777,652
Series B Convertible Preferred Stock | Common Stock | Purchase Agreement | Minimum
Temporary Equity [Line Items]
Percentage of common stock outstanding shares	4.99%
Series B Convertible Preferred Stock | Common Stock | Purchase Agreement | Maximum
Temporary Equity [Line Items]
Percentage of common stock outstanding shares	19.99%

Series B Convertible Preferre_4

Series B Convertible Preferred Stock - Summary of Changes to Series B Preferred Stock (Details) - USD ($)	12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Temporary Equity Disclosure [Abstract]
Mezzanine Equity Beginning Balance, amount	$ 4,804,819
Issuance of preferred stock		$ 4,638,521
Dividends accrued	365,979	127,541
Accretion of discount for warrants	103,350	38,757
Mezzanine Equity Ending Balance, amount	$ 5,274,148	$ 4,804,819

Non-Cash Activities for State_3

Non-Cash Activities for Statements of Cash Flows - Schedule of Consolidated Statements of Cash Flows for Non-Cash Activities (Details) - USD ($)		6 Months Ended	12 Months Ended		44 Months Ended
	Feb. 06, 2023	Dec. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Non-Cash Activities for Statements of Cash Flows [Line item]
ROU assets financed by lease liabilities			$ 680,703	$ 369,574
Contribution of intangible assets to Trigall in exchange for equity investment and promissory note			(1,750,000)
Warrants issued for financial commitment asset			1,894,901
Dividends accrued for participating securities			365,979	127,541
Mezzanine equity series B detachable warrant			103,350	38,757
Conterra [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Settlement of long-term debt principal, interest and other related costs	$ 6,600,000	$ 400,000		$ 400,000	$ 3,100,000
Vision Bioenergy Oilseeds LLC [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest	(5,500,000)
Vision Bioenergy Oilseeds LLC [Member] | Conterra [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Settlement of long-term debt principal, interest and other related costs	6,900,000
Shell Oil Products US [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Fair market value of purchase option	700,000
Shell Oil Products US [Member] | Vision Bioenergy Oilseeds LLC [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Fair value of payment based on discounted value	5,700,000		5,747,127
Fair market value of purchase option	695,000		695,000
Contribution of property, plant and equipment and inventory to Vision Bioenergy for equity interest	(5,532,694)		(5,532,694)
Shell Oil Products US [Member] | Vision Bioenergy Oilseeds LLC [Member] | Conterra [Member]
Non-Cash Activities for Statements of Cash Flows [Line item]
Settlement of long-term debt principal, interest and other related costs	$ 6,860,838		$ 6,860,838

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Line of Credit - CIBC - USD ($)	Sep. 25, 2023	Mar. 22, 2023
Prime Rate
Subsequent Event [Line Items]
Basis spread on variable rate		2%
Subsequent Event
Subsequent Event [Line Items]
Debt instrument, fee amount	$ 75,000
Subsequent Event | Prime Rate
Subsequent Event [Line Items]
Increased applicable margin interest rate	0.50%
Basis spread on variable rate	2.50%